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1Introduction
1. Aim of the study
Current bioprosthetic valves are far from ideal. The reasons for this lie on one hand
with the complexity of the native aortic valve and on the other with inherent limita-
tions of bioprosthetic valve themselves. A tissue engineered aortic valve involves the
development of a vital construct which mimics the native aortic valve and which can
replace diseased aortic valves without the limitations of currently available pros-
thetic valves. Tissue engineering was defined by The World Technology Panel Report
[1] as: ‘The application of principles and methods of engineering and life sciences to obtain a
fundamental understanding of structure-function relationships in novel and pathological mam-
malian tissues and the development of biological substitutes to restore, maintain or improve tis-
sue function’.
When finally manufactured a tissue engineered aortic valve will be required to repli-
cate most, if not all, of the biological functions of a normal aortic valve and the nor-
mal valve’s morphodynamic behaviour [2] in relation to the heart.
Although tissue engineering is being currently applied to neural tissue, skin, bone,
cartilage and liver among others [3], to date, the successful development of a func-
tional tissue engineered aortic valve has not been achieved. Nevertheless, a tissue-
engineered valve is a promising concept that can revolutionize the treatment of val-
vular heart disease with global impact. At present several approaches to tissue valve
engineering are evolving and include the use of synthetic or decellularized allogenic
or xenogenic valve matrices followed by attempts to repopulate the matrices with
appropriate autologous cells, either in vitro or in vivo after implantation [4,5]. In
these approaches several critical issues need to be addressed and they include the
choice of matrices, cell type, whether to repopulate in vitro or rely on in vivo repopu-
lation as well as the performance of such constructs in a large animal model before
clinical use as is required by controlling agencies such as the Food and Drug Admin-
istration (USA) and the International Standards Organization (ISO 5840).
This study addresses some fundamental aspects in the development of a functional
tissue engineered aortic valve using xenogenic scaffolds and fibroblastic mesenchy-
mal cells.
Investigators in this field are faced with a major problem. No tissue engineered valve
has yet been successfully developed and the exact requirements of such a prostheses
are difficult to specify, a task made all the more difficult, since the biology and bio-
2mechanics of native aortic valves have only recently begun to be defined [6-9]. In fact,
surrogate endpoints such as hemodynamic performance; calcification and capacity
to grow have yet to be established. Much of the investigations in this study form part
of this new research domain and cannot be situated in a huge realm of previous
research. What is known is that the native aortic valve structure and function is com-
plex as described below and that they succumb to disease. Further, it is known that
current prosthetic valves do not match the native valve’s performance due to inher-
ent limitations. To illustrate the complex challenges to aortic valve tissue engineer-
ing and the approaches that have been adopted to meet them in this study, a descrip-
tion of the complex nature of the aortic valve becomes obligatory.
2. The Challenges
2.1 The Complex Structure Function Relationships of the Aortic Valve.
2.1.1 The Heart and its Valves
A healthy human heart weighs approximately 200 to 400 grams, pumps approxi-
mately 5 to 6 litres of blood per minute when beating at a rate of 70 beats /minute
and ensures a continuous and adequate supply of oxygen to the vital organs. In fact,
in a single day such a heart would beat more than 100,000 times, pump more than
8,000 litres of blood and is capable of increasing its output three to four times dur-
ing exercise. Blood is pumped through the large vessels connected to the heart and
the heart’s valves serve to direct this flow in one direction by not allowing back flow
or regurgitation. Blood returns from the body to the right atrium of the heart via the
vena cava and passes through the tricuspid valve to the right ventricle. It then goes
through the pulmonary valve to the lungs, where it is oxygenated and returned to
the left atrium via the pulmonary veins. It then passes through the mitral valve to
the left ventricle from where it goes through the aortic valve to the aorta and the rest
of the body (Fig 1).
The cardiac cycle can be divided into two stages. The first is diastole during which
the ventricles briefly relax before filling with blood. The second stage is systole,
which represents the period of contraction and ejection of blood from the ventricles
(Fig 1).
The aortic valve as such is subjected to cyclical systolic pressures in preventing back-
ward flow into the left ventricle. The pressure changes during the cardiac cycle are
illustrated in Figure 2, in which seven phases are indicated [10]. During the first
3phase the atria contract (Phase 1), ejecting blood into the ventricles through the tri-
cuspid and mitral valves (A-V valves). The subsequent increase in ventricular pres-
sure closes the A-V valves. At the beginning of systole, ventricular isovolumetric con-
traction occurs (Phase 2) with a rise in ventricular pressure, which results in the
opening of the aortic and pulmonary valves and the ejection of blood into the corre-
sponding vessels (Phase 3). The aortic pressure rises above that of the emptying ven-
tricles with closure of the aortic valve. Following the rapid ejection, both the pres-
sure in the ventricles as well as in the aorta is reduced (Phase 4). The ventricles then
isovolumetrically relax (Phase 5) and end the systolic phase after approximately 0.35
seconds. The diastolic stage follows the end of systole, with rapid filling of the ven-
tricles (Phase 6) once the ventricular pressure falls below the atrial pressure with
opening of the A-V valves. During this period, the flow of blood from the aorta to
Fig. 1. llustration of the anatomy of the heart and its systolic and diastolic functions.
Reproduced with permission.
(Image copyright Texas Heart Institute, www.texasheartinstitute.org).
4the peripheral circulation continues, and the aortic pressure gradually decreases.
The rapid ventricular filling is followed by a slower, reduced ventricular filling phase
(Phase 7).
2.1.2 The Aortic Valve Structure and Function.
The aortic valve opens and closes approximately 100,000 times per day and approxi-
mately 3 billion times in its life span [11], during which the high complexity of its
structure-function relationship, guarantees optimal hemodynamic function and
remarkable durability.
Figure 3 illustrates the anatomy of the normal aortic valve and its relations. Each
valve is comprised of three semilunar leaflets referred to as cusps and which are
inserted into the aortic wall in a semilunar fashion and in fact separates hemody-
namically the aorta from the left ventricle. The aorta bulges behind the attachment
Fig. 2. The Cardiac Cycle- events occurring during the cardiac cycle (Klabunde, 2004) [10].
5of each leaflet-giving rise to the aortic sinuses, which are expanded portions of the
aortic wall. Distally, the aortic valve is continuous with the ascending aorta and
proximally it is attached to the left ventricle. The surface of the leaflet facing the
aorta is called the aortic surface and that facing the ventricle, the ventricular surface.
Each leaflet has an average thickness of 0.6mm, which varies considerably over the
surface [12] and is named according to its adjacent sinus. The ostia of the left and
right coronary arteries open into the right and left coronary sinuses respectively. The
third sinus has no coronary artery opening and is referred as the non coronary sinus.
Accordingly, the three semilunar leaflets are referred to as the right, left and non-
coronary leaflets respectively [11].
The morphological design of the aortic valve results in hemodynamic flow charac-
teristics that are coupled to cardiac contraction in morphodynamic behavior. Dur-
ing systole the commissures, points of attachment of adjacent leaflets pull outward
causing the leaflets to open. Simultaneously, the base of the valve moves inwards
causing a decrease in base perimeter. During diastole, vortices developed in the
sinuses, along with an inward movement of the commissures and outward move-
ment of the base close the valve [14].
The aortic leaflets do not passively open and close during the cardiac cycle. During
their movements the leaflets undergo repetitive changes in conformation and
Fig. 3. Anatomy of the aortic valve. the ventricular surface of the leaflet faces the ventricle and the 
aortic surface, the aorta. (Reproduced from Anderson RH et al.[ 13]).
6dimension, varying their surface area by as much as 50% to ensure closure while
withstanding the cyclical pressures. This extraordinary function is still not fully
understood and results from complex actions and interactions of the elements com-
prising the leaflet [15,16].
Each valve leaflet is made up predominantly of structural (collagen and elastin) and
cellular (Interstitial cells with fibroblast and smooth muscle characteristics,
endothelial cells) elements that organize to form three distinct layers (Fig.4); (a) the
ventricularis, (b) the spongiosa and (c) the fibrosa. The micro architecture is such
that the layers display structural and non-structural regional specialization giving
the valve anisotropic qualities whereby its properties are not the same in all direc-
tions [17]. Collagen fibers in the fibrosa are compact and arranged both longitudi-
nally and radially, with the radial fibers being more corrugated (crimped) than longi-
tudinal ones. The collagen present in the leaflets consists of collagen types I, III and
V [18]. The ventricularis has less dense, longitudinally arranged, corrugated collagen
and radial elastin fibers. Elastin is considerably less stiff than collagen and its coiled
hydrophobic structure allows its molecules to slide over each other and provide
stretch to maintain structural integrity and to provide recoil [19]. The spongiosa
Fig. 4. Schematic representation of the different layers of the aortic valve leaflet, showing that the 
fibrosa layer is corrugated, enhancing the ability to stretch in a radial direction. (Reproduced  from 
Broom ND: Connective tissue function and malfunction: a biomechanical perspective. Pathology 
1988; 20:93.)
7contains loosely arranged collagen and abundant proteoglycan [17]. The proteogly-
can content of aortic leaflets consists mainly of Dermatan and Chondroitin sulfate,
and their water retaining properties allows for the dampening of mechanical forces
developed during valvular function and maintaining viscoelastic properties of the
tissue [20-23]. This micro architecture and its associated micro mechanics impart
specific qualities to the natural valve; (a) fiber rearrangement and remodeling allow
the leaflet to be soft and pliable as they open during systole but stiff and extended
when closed to withstand backward pressure an prevent leaks into the left ventricle.
Closure is facilitated by increased surface area accomplished by the flattening of cor-
rugations in radial collagen fibers and elastin stretch while stiffness is generated by
longitudinal fibers that flattening out by losing their corrugations [24] (b) there is
differential movement of the leaflet layers, which slide and increase surface area, (c)
forces generated by differential movement [25] and closure of the leaflets is absorbed
by the spongiosa and transferred to the elastic aorta, thereby resulting in a mini-
mum of force on the closed leaflet, (d) the fibroblasts which constitute a heterogene-
ous mesenchymal cell population with predominantly the myofibroblastic pheno-
type communicate with each other by an as yet not understood mechanism and con-
tinuously replenish and remodel the structural elements as they become damaged
from repetitive function [24].
Moreover the movement of the valve has been shown to precede the movement of
blood, and thus to occur before the hemodynamic events [26]. It is also known that
valve tissue is innervated by sympathetic, parasympathetic and sensory nerve fibers
and those different parts of the valve can react to circulating vasoactive products
[27]. Regional specification in gene expression by the cells of the valve is believed to
be responsible for these observations [28].
2.2 Heart Valve Disease.
The United Nations population report projects an increase in the world population
between 2005 and 2050 from 6.4 to 8.9 billion inhabitants or more depending on
world fertility pattern (Fig.6).
Valvular heart disease is a serious clinical condition resulting from the dysfunction
of one or more of the heart’s valve. The incidence and prevalence of valve disease is
increasing worldwide due to the world population's increasing age (Fig. 7) and the
world’s failure to address the problem of rheumatic cardiac disease in developing
countries and in indigenous populations in the developed world [29] (Fig. 8). The
third world will have the largest increase in world population [30] and due to limited
resources not all patients requiring heart valve replacement will even have access to
8this treatment. Strategies to address this global problem [31] including development
of an affordable and durable prosthetic valve could have significant impact.
At present, in the USA alone, approximately five million patients are diagnosed with
valvular heart disease each year and according to the American Heart Association
2003 Heart and Stroke Statistical update, valvular heart disease is responsible for
almost 20,000 deaths annually and is a contributing factor in almost 42,000 [32].
Aortic valve disease alone accounts for 63% of deaths and the mitral valve (14%), pul-
monary (0.06%), tricuspid (0.01%) or combination accounting for the rest. More
than 100,000 US patients need replacement of their dysfunctional valves with a
prosthetic valve each year and more than 300,000 prosthetic valves are sold world
wide annually [33].
Disease of the aortic valve can result in stenosis, regurgitation or a combination of
both and leads to pressure overloading of the heart due to a restricted valve opening
or volume overloading due to inadequate valve closure. In the USA, valvular aortic
stenosis and regurgitation affect about five out of every 10,000 people [34]
Fig. 6. Population of the world, 1950-2050, by projection variants.
9Fig. 7. Life expectancy at birth for the world and major areas, 1950-2050.
Fig. 8. Population dynamics by development groups, 1950-2050.
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The prevalence of aortic stenosis increases with age showing an occurrence of sclero-
sis in 26% of adults above 65 years of age and stenosis in 4% of adults above 84 years
of age [35-37]. Age related aortic degenerative aortic stenosis is the most common
cause of isolated aortic valve disease in adults. It is typified by subendothelial infil-
tration by proteins and lipids and a progressive stiffening of the leaflet due to calcifi-
cation [38-40]. Native aortic valve cusps are visibly opaque after the age of 20 years
[41] and their thickness increases significantly with age as a result of thickening of
the fibrosa and ventricularis layers [38]. Lipid accumulation with formation of
atheromas is usually observed after the age of 30 years [43]. With aging, calcific
deposits have been reported to occur in more than 20% of individuals older than 75
years [44] and are usually found within lipid accumulations deep in the fibrosa near
to the spongiosa layer. Ultra-structurally, this calcification is associated with debris
derived from degenerated cells [45] such that native aortic valve calcification is
thought to be a degenerative change. Moreover, with age, the anatomy of the aortic
valve changes, with progressive stretching, fibrosis and lipid accumulation as well as
an increase in valvular diameter [46,47]. It has been suggested that subtle abnormal
changes in cusp shape and size, which result in increased hemodynamic stresses,
may contribute to the degenerative process leading to aortic stenosis [48]. In addi-
tion valvular abnormalities can be caused by both congenital and acquired diseases
such as in bicuspid aortic valves and rheumatic disease.
The mechanisms of age related calcification of the aortic valve has been attributed to
progressive degeneration involving dystrophic calcification, which results from
injury due to long-standing and repetitive mechanical stress. Although still not fully
understood, calcific deposits in the aortic valve are dependent on the biochemistry
and structure of the tissue as well as the chemical environment. The relationship
between calcification and the process of arteriosclerosis is not clear [49]. A close rela-
tionship has been suggested by studies showing calcific deposits associated with
lipid accumulations in the aging aortic valves especially in areas of the fibrosa where
fibroblasts are diminished in number and where calcification and lipid are associ-
ated with fragments of degenerated fibroblasts [50]. It has also been suggested that
in aging cells, extra-cellular calcium reacts with membrane phospholipids of deterio-
rating cells with formation of calcium phoshate in a similar manner as described for
bioprosthetic valves in the introduction of this manuscript. A growing number of
studies have recently challenged the view that aortic calcification is merely due to
aging and have suggested a role for non collagenous extra-cellular matrix proteins
such as osteopontin which bind to hydroxyapatite and may play a role in calcifica-
tion [51-54]. Moreover correlations between calcification, macrophage accumula-
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tion and osteopontin expression in aortic valve stenosis have been reported,
although the exact role of osteopontin is unclear [55-58].
Patients with congenital bicuspid valves are predisposed to early aortic stenosis due
to abnormal leaflet structure leading to fibrosis and calcification [ 59]. Under 70
years of age, congenital calcified bicuspid valves account for 50% of all cases where as
in above 70 years of age, degenerative calcific stenosis account for 48% of cases [ 60].
Rheumatic disease, which results in fusion of the leaflets, is also a cause of aortic
stenosis. Rheumatic aortic stenosis is rarely isolated and usually occurs in conjunc-
tion with mitral valve stenosis [59]. Other conditions less frequently associated with
aortic stenosis are Paget’s disease, renal disease and ochronosis [61–63].
Aortic stenosis results in chronic left ventricular pressure overload with subsequent
ventricular adaptation. Initially the left ventricle compensates for the increased pres-
sure by pumping more forcefully to maintain its cardiac output. With persisting ste-
nosis, the ventricle compensates by increasing its muscular mass whereby it gener-
ates compensatory force to maintain cardiac output [64]. Mature cardiac myocytes
increase their volume with thickening of the ventricular wall referred to as concen-
tric compensatory hypertrophy [64]. Mature cardiac muscle cells or myocytes do not
divide and compensatory hypertrophy occurs by an increase in myocyte volume,
which is limited. In untreated, longstanding aortic stenosis compensatory hypertro-
phy fails leading to dilate cardiomyopathy and cardiac decompensation with a loss
of myocytes. When symptoms develop, the prognosis becomes poor and the average
survival is 2 to 3 years for patients with symptoms of angina or syncope, and 1 to 2
years for those who develop congestive heart failure [65].
Aortic valve insufficiency may be caused by abnormalities of the leaflets, the aorta,
or a combination of both and is characterized by inadequate closure of the valve. Iso-
lated aortic regurgitation is rare and it occurs most commonly in combination with
aortic stenosis. When the pathological abnormalities are confined to the aorta, the
leaflets remain anatomically normal. The latter patients have progressive dilatation
of the aortic sinuses and on occasion dilatation of the annulus of the valve with aor-
tic insufficiency. Most are idiopathic [66] (annuloaortic ectasia) but may be associ-
ated with a with a spectrum of pathology which include Marfan syndrome [67], aor-
tic dissection and aortitis [68-69] as well as rare connective tissue disorders such as
Reiter’s disease and Ehlers-Danlos syndrome and rheumatoid arthritis [70-73].
Unlike aortic stenosis, both volume and pressure overload of the left ventricle
occurs. The compensatory changes of the ventricle involve eccentric hypertrophy.
Myocytes do not thicken but add myofibrils in series with an increase in ventricular
volume[74]. The exact molecular mechanisms involved remain unknown but recent
evidence suggests that stress activates calcium-dependent kinases, which induces
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vasoactive peptides (angiotensin II, neuregulin and other growth factors) leading to
increased myofibril production and decreased degradation at a cellular level and
consequent hypertrophy [75]. Importantly, myocyte hypertrophy in aortic stenosis
leads to an increased synthesis of myofibrillar protein, where as in aortic insuffi-
ciency the increased myofibrillar protein content is mainly due to decreased degrada-
tion [76]. As systolic stress increases and persists in time, the ventricular wall also
thickens and develops fibrosis possibly due to ischemia, myofibrillar degeneration or
myocyte apoptosis mediated by death proteins such as the mitochondrial death pro-
tein Nix [77]. Subsequently, the ventricle becomes over distended at which point the
myocardium loses its reserve (wall tension) and the heart decompensates. Although
chronic aortic insufficiency is generally well tolerated for years, acute aortic insuffi-
ciency, as for instance in the case of acute aortic dissection, is not and can lead to
death. The prognosis in chronic patients who become symptomatic is poor with
death occurring within 4 years after development of angina and within 2 years after
the onset of congestive heart failure [68].
2.3 Treatment of Heart Valve Disease.
Treatment for valvular heart disease depends on the type and severity of the disease
and involves either medical or surgical therapy. Medical therapy in patients with aor-
tic insufficiency is not able to significantly reduce regurgitant volume due to the val-
vular incompetence and because of the low diastolic pressures that are observed due
to the failure of the valve to close sufficiently. As such medical therapy is usually
directed at reducing the systolic pressure (hypertension) in an attempt to reduce the
stress in the ventricular wall (wall stress) and ease distension and as such to improve
ventricular function. The drugs of choice are vasodilators, which have been shown to
be beneficial in delaying surgery, or treating patients who are not candidates for sur-
gery [79-81]. In patients with symptomatic aortic stenosis, medical treatment is usu-
ally reserved for patients who are not candidates for operation since the treatment of
choice is surgical. In these patients pharmacological therapy is used only as adjunc-
tive treatment for complications associated with aortic stenosis such as cardiac fail-
ure (e.g. angiotensin converting enzyme inhibitors, diuretics), fluid retention (diu-
retics), arrhythmias and hypertension [82-83].
Surgical treatment of aortic valve disease includes reconstructive procedures that do
not replace the valve and valve replacement. In neonates and young children with
congenital aortic stenosis for instance, surgical techniques are used to mobilize the
leaflets and thus allow the child to grow to adolescence at which time other proce-
dures can be employed. In patients with aortic aneurysms or dissection and in whom
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the aortic leaflets are not affected, the valve is preserved in some procedures that
completely resects the diseased aorta and replace it by synthetic material [84-85] or
in other techniques a less radical resection [86] of the aorta is employed and the valve
is mobilized and inserted inside a synthetic Dacron tube which is sewn in place to
replace the aorta. Both techniques preserve the native valve, the first preserving its
distensibility and the second is aimed at preventing future dilatation. Although
some diseased aortic valves can be repaired a large number of valves are not suitable
for repair and need replacement [87]. Consequently, the main treatment for diseased
aortic valves is surgical replacement, which can significantly improve the life expect-
ancy of patients. A 60 year old man for example with severe aortic stenosis has
approximately 4 years to live, but after valve replacement his life expectancy increases
to approximately 13 years [88]. However, a 60 year old man in the general population
has a life expectancy of 18 years which is 5 years longer than that of the valve recipi-
ent and it has been suggested that most if not all of this difference is related to the
use of current bioprostheses which do not match the native valve and are sub opti-
mal.
Limitations of Current Prosthetic Valves.
Current commercial prosthetic valves can be grouped into three categories (Fig 9):
(a) bioprostheses, (b) homograft valves and (c) mechanical prosthetic valves. In addi-
tion to specific disadvantages, all currently available prosthetic valves are a-vital and
lack the ability to grow.
Bioprosthetic valves
Bioprostheses are derived from animal or human tissue after chemical treatment.
Most are manufactured from porcine valves or bovine pericardium after treatment
with the monoaldehyde glutaraldehyde [88] which are available in various configu-
rations and are either affixed to a supporting metal or plastic stent (stented valves)
or not (stentless valves). These valves require no anticoagulation therapy [89] and
despite disadvantages they have in the past, and continue to serve patients well with
a durability of 15 to 20 years [90-94]. While high functional stresses associated with
tissue fixation onto the stents can result in accelerated tissue fatigue with resulting
tears [95], in presently used bioprosthetic valves, calcific deterioration is the main
cause of valve failure [96]. Indeed 20-30% of porcine valves require reoperation
within 10 years and 50 % within 12-15 years. Valve failure is more rapid in younger
patients (almost 100% within 5 years in patients <35 years of age) [97-99].
Glutaraldehyde treatment of porcine aortic valves for human implantation was first
introduced in 1969 [100] and the majority of bioprosthetic valves implanted cur-
14
rently are covalently cross-linked with glutaraldehyde which stabilizes the tissue
while reducing its antigenicity and sterilizing it to some extent. The limited durabil-
ity of glutaraldehyde fixed bioprosthetic valves has been attributed to altered
mechanical properties, antigenic properties of the cells, glutaraldehyde interactions
and the calcification potential of cell membrane [100-104]. In addition, in children,
in whom bioprosthetic valve failure is observed more commonly than in adults a
possible involvement of high serum phosphate and osteocalcin as well as enhanced
metabolism of parathyroid hormone and vitamin D has been suggested [105-107].
While it is widely acknowledged that glutaraldehyde treatment results in a reduction
of immunological recognition of the xenogenic tissue and its stabilization to degra-
dative enzymes in humans [108], glutaraldehyde has been suggested to be a cause of
pathological calcification [101,109]. In bioprosthetic valves, glutaraldehyde intro-
duces thermally and chemically stable cross-links or Schiff-bases with amino groups
in collagen, which become compromised with time and result in a leaching out of
glutaraldehyde [110]. Such free aldehydes have been shown to be easily oxidized to
carboxylic acid, which is a potential site for calcium binding [111,112]. Glutaralde-
Fig. 9. Prosthetic Heart Valves. Right to Left upper row: stented bioprostheses (Edwards 
pericardial valve®), a stentless porcine valve (Toronto SPV ® valve) and a human homograft. 
Lower row: a Starr Edwards® ' ball-cage' valve, a monoleaflet tilting disc valve (Medtronic hall®) 
and a bileaflet mechanical valve (St. Jude Medical®)
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hyde also stiffens and alters the biomechanical characteristics of biological valvular
tissue whereby the collagen is locked in geometric configuration. Such alterations
are associated with demonstrable changes in leaflet motion which produce abnor-
mal stress patterns causing buckling, accelerated calcification and eventual tissue
failure [113]. Moreover it is known that bioprostheses show progressive depletion of
proteoglycans both in vitro and in vivo [114,115]. As such because proteoglycans
contribute significantly to the viscoelastic properties and accommodation of stresses
in the leaflet, their loss may influence mechanical deterioration.
In addition, glutaraldehyde cross-linked valves are and remain non-viable tissues
without opportunity for either growth or tissue renewal. Their cells are no longer
biologically dynamic and as such are incapable of replenishing and maintaining the
extra cellular matrix. After implantation these valves are not repopulated with host
cells which at least partially can be explained by the cytotoxicity of glutaraldehyde
and the inability of cells to penetrate the cross-linked matrix [110,116]. Further-
more, although stable cross-links in cellular and extra cellular matrix proteins
reduce immunogenicity, porcine tissue retains a residual ability to trigger an
immune response that can activate macrophages, which in turn can obtain an oste-
oblast calcium depositing phenotype [117]. Moreover, it is well established that cell
and the cellular membrane provoke early calcification of biological heart valves,
whereby a direct relation between specific antibody response and the calcification of
porcine tissue has been demonstrated [104,118]. Furthermore phosholipids present
in cell membranes are believed to separately initiate calcification by forming calcium
phosphate crystals with free serum calcium [103,119,120].
To reduce their propensity to calcify manufacturers employ several anti-calcification
treatments in the production of bioprosthetic valves. However, they have not yet
resulted in significantly improved valve durability (amino-oleic-acid, ethanol) [121].
Homograft valves
Human homografts (also referred to as allografts) are intact human valves and the
first reported use of a cadaveric homograft to treat aortic valve disease was by Mur-
ray in 1956 [103] that implanted valves in the descending aorta of patients. Sir Don-
ald Ross in the Lancet reported the first use of the homograft valves in the aortic or
orthotopic position in 1962 [122].
Valves are usually obtained from beating heart donors whose heart are unsuitable
for transplantation or from cadavers, and are either stored by cryopreservation
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before use [123,124] or are used after antibiotic sterilization within 60 days [125]. At
present these valves are most commonly stored by cryopreservation before use as this
provides a long shelf life in view of a shortage of donors [126]. In fact a major limita-
tion to the use of homografts is their limited availability especially in the pediatric
sizes.
Cryopreserved human valves (homografts) show durability comparable to the best
xenografts and can last for 20 years despite no HLA or ABO matching [127].
Although they perform well, these valves are also avital [128,129] and succumb to
fibrosis and calcific deterioration.
The occasional survival of viable donor fibroblasts in cryopreserved homografts have
been reported and it is likely that some cells persist for at least some time [126]. The
functionality of these cells is unknown. Several attempts have been reported to mod-
ify homografts by maintaining cellularity [126] and to improve long term structural
integrity [130]. However if such valves remained vital, their cell may prove detrimen-
tal by inciting their own rejection [131]. Multiple studies have demonstrated the
generation of donor-specific alloantibodies directed against human leukocyte anti-
gens (HLA) class I (A and B antigens) and II (DR antigens) in valve recipients
[132,133 ] However, despite consistent evidence of antibody formation directed
against the HLA antigens, the clinical significance of these observations remains
unclear [134,135].
Homografts have several advantages and these include excellent hemodynamic pro-
files [136,137] more similar to native valves, no requirement for anticoagulation and
a low rate of infection compared to other prosthetic valves [138,139,140]. In fact in
endocarditis they remain the prostheses of choice, especially when the aortic annu-
lus is disrupted by infection. They remain however, a-vital structures with limited
durability even after implantation and show structural failure with time, which
approximates 19% to 38% at 10 years and 69% to 82% at 20 years. [138,141].
Mechanical valve prosthesis
A mechanical valve is constructed from man-made materials (non biological). The
first mechanical valve, developed in 1960, was of the ‘’ ball and cage’’ design of Starr-
Edwards type. This has proven to be a very durable valve over time [142] and in fact
some valves are still functioning today more than 30 years after implantation. How-
ever poor biocompatibility owing to damage caused to blood elements and the need
for high doses of anticoagulation plagued these valves and led to the search for bet-
ter designs which led to development of mono leaflet tilting disc valves shown in fig-
ure 9. Although these valves show improved hemodynamics, they still required life
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long anticoagulation and were sometimes considered noisy by patients [143]. Ever
since, mechanical valve design has continuously improved to the newer generation
of valves, namely the bileaflet valves. Presently mechanical valves are constructed
from materials such as polymers, metal and pyrolytic carbon and they show life long
durability and excellent hemodynamics and more than 60% of heart valve replace-
ments are made using mechanical prostheses [144].
Nevertheless, although more durable than bioprosthetic valves, mechanical valves
remain less biocompatible. Their surfaces are thrombogenic and their major limita-
tion is the need for anticoagulation with its associated risks in recipients
[145,146,147]. They are associated with substantial risk of systemic thromboemboli
and thrombotic occlusion largely owing to the non-physiologic surfaces and abnor-
mal flow characteristics produced by rigid occluders [146,148]. Moreover these valves
cannot be placed in patients in whom anticoagulation is contraindicated. In young
expectant mothers for instance, they pose an increased risk for bleeding complica-
tions [149]. In patients who have received a mechanical valve and are on anticoagula-
tion therapy the risk of hemorrhage during long term anticoagulation therapy is 2 to
5 per patient/ year, with cerebral, gastrointestinal or retroperitoneal bleeding being
the most common in mechanical valve recipients on anticoagulation [150,151].
A Tissue Engineered Solution.
A tissue engineered aortic valve constructed from scaffolds and cells, will overcome
the limitations of currently available prosthetic valves by regenerating and maintain-
ing its extra cellular matrix, require no anticoagulation therapy, avoid immunologi-
cal rejection and theoretically be capable of growth. The critical issues facing such a
valve include where to start in terms of scaffold material and how to accomplish the
requisite recellularization. The present study addresses some of these issues, which
are at the foundation of developing a tissue engineered aortic valve.
In Chapter 1, we describe calcification in glutaraldehyde aortic valves obtained from
kangaroos and pigs and assess the hydrodynamic properties of their respective
matrices. In Article I.1, we examined the calcification potential of kangaroo aortic
valves for two reasons. Firstly we wanted to check the rate of calcification of these
valves compared to that of porcine valves in the rat model and hence their reported
potential as bioprosthetic valves. For instance observation of significantly higher cal-
cification compared to porcine valves might rule them out as potential matrices
despite other advantages as described later. Secondly the calcification rates in these
biological valves could be useful in eventual comparative assessment of the calcifica-
tion potential of decellularized matrices.
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In Chapter 2 we illustrate the nature of calcific deposits within the leaflet layers of an
explanted bioprosthetic valves in an attempt to understand their destructive effect
on the extra cellular matrix. This study is part of an explant analysis study initiated
in our department to better understand the mode of failure of bioprosthetic valves
and aid us in avoiding similar pitfalls in engineering a valve. This study was unique
in that it afforded us the rare opportunity to evaluate different modes of failure in
the same valve, namely calcific and non calcific destruction of the matrix and report
it for the first time. It was obvious that calcification was strongly associated with the
extra cellular matrix. Such information could also prove useful in assessing eventual
calcific destruction in tissue engineered valves or matrices.
Satisfied that kangaroo aortic valves had a comparable rate of calcification to por-
cine valves, we proceeded to develop matrices of both types. In Chapter 3 the hydro-
dynamic properties of porcine and kangaroo aortic matrices prepared from aortic
valves are evaluated. While porcine xenogenic matrices are currently used in tissue
valve engineering, ours is the only group reportedly investigating kangaroo aortic
valve matrices and to justify their use we needed to ensure satisfactory hydrody-
namic performance, at least compared to similar porcine matrices, since this was not
done before.
In Chapter 4, we compared the biomechanical properties of porcine aortic valves
before and after cryopreservation and that of non-decellularized leaflets. The decel-
lularization procedure employed and described was time consuming (5 days). It
became obvious to us that using our protocol, it would not be practical nor efficient
to prepare matrices each time one is need and especially so in a clinical setting. We
therefore investigated the feasibility of preserving such matrices by cryopreservation.
We evaluated the mechanical effects of both decellularization and cryopreservation
on matrices.
In Part III, we describe a model for transdifferentiating fibroblasts to myofibroblasts
for use in tissue valve engineering and the use of growth factor to modulate their
proliferative and invasive properties (Chapter 5 and Chapter 6). Such manipulations
allow us to have sufficient quantities of myofibroblasts in order to seed matrices and
to enhance their repopulation.
In Chapter 7, we investigated the inherent calcification potential of both porcine
and kangaroo matrices in sheep. Information from such studies could be useful in
improving the quality of matrices and in understanding eventual failure of tissue
engineered valves.
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Part I
Matrix Procurement
To start with, a matrix, which replicates functionally if not structurally, the perform-
ance of the native aortic valve needs to be selected. Two main types of scaffold mate-
rial are currently being investigated, namely decellularized biological valve matrices
and those fabricated from biodegradable polymers [1, 2]. A polymer based approach
must replicate the performance characteristics of the native aortic valve and no such
polymer has yet been developed [3]. Secondly, although polymers have been applied
in the tissue engineering of bone and skin, present knowledge into their use in tissue
valve engineering is insufficient to prevent a foreign body fibroblast reaction rather
than establish a normal tri-laminar structure with appropriate proportions of extra-
cellular matrix, proteins and multiple cell types with density and location character-
istic of a functional aortic valve [4]. Biological matrices derived from porcine valves
on the other hand, avoid many engineering design problems and are used on the
assumption that a decellularized xenograft scaffold, devoid of cells is potentially less
immunogenic than cellularized bioprosthetic valves [5], which have to be treated
with glutaraldehyde before implantation.
While biodegradable polymer and biological scaffolds have been tested in vivo, alter-
native material being tested for use as scaffolds in tissue valve engineering includes,
collagen, hyaluronan and fibrin. A major problem with the use of reconstructed col-
lagen as scaffolds is the observation that within such scaffolds, cells rapidly enter
apoptosis. Giachelli and colleagues have reported that combining collagen with chi-
tosan, which is derived from crustacean shells, show an improvement compared to
the use of collagen alone [6]. Others, [7] reported satisfactory proliferation of myofi-
broblasts in collagen scaffolds when these cells are cultured in combination with
endothelial cells. More recently by varying the concentration of collagen, Taylor and
co-workers, using the technique of Rapid Prototyping, which can potentially allow
for the development of three dimensional scaffolds, have shown that scaffolds con-
taining 1% of collagen allowed cell proliferation to a greater extent than those based
on 2% or 5% collagen [8].
The visco-elastic properties and biocompatibility of the glycosaminoglycan hyaluro-
nan [9, 10] has led to investigations of its use as a potential scaffold in tissue valve
engineering. Vesely and co-workers, working with hyaluronan gels, cross-linked with
divinyl sulfone [11], have reported that such constructs have elastic properties com-
parable to the aortic valve cusps and might find use in the central fibrosa portion of
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cusps, possibly combined with collagen in one construct. As an alternative to colla-
gen, a number of investigators are also considering the use of fibrin gels [12].
Collaborative work between the Departments of Cardiac Surgery, University Hospi-
tal Ghent and the Departments of Cardiothoracic Surgery of Fremantle Hospital,
University of Western Australia, Perth and The Prince Charles Hospital , University
of Queensland, Brisbane, Australia, has led to the use of kangaroo heart valves as an
alternative source of biological matrices.
Kangaroos are upright and more similar in posture to humans compared to pigs.
And their aortic valves are morphologically and histologically different from porcine
aortic valves. In particular, kangaroo aortic valves have thinner leaflets with a more
compact collagenous matrix compared to porcine aortic valves and unlike porcine
aortic valves they have no muscular shelf in the right coronary cusp [13, 14]. Such a
muscular shelf, in addition to partially obstructing flow, also necessitates muscular
decellularization when preparing a-cellular biological scaffolds. Its absence in the
kangaroo valve avoids both possible obstruction with hydrodynamic consequences
as well as the need for muscle decellularization. Indeed, Weinhold and co-workers
who implanted whole kangaroo aortic valves in the tricuspid position of sheep [14]
reported superior hemodynamic performance of kangaroo aortic valves compared to
porcine aortic valves. A thinner kangaroo leaflet matrix might also require less cells
to repopulate. Investigations in our laboratory confirmed that while similar struc-
tural elements are present in kangaroo and porcine valves, their distributions in the
fibrosa, ventricularis and spongiosa of the leaflets are different in these two species,
with kangaroos having a thinner spongiosa layer and a relatively thicker ventricula-
ris layer.
While there is no standardized method, typically, matrices are prepared from biolog-
ical valves by cell lysis using alternating treatments of hypertonic and hypotonic
solutions followed by detergent extraction and enzymatic digestion [15].
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Part II
Storage of Matrices by Cryopreservation: 
Effects on the Biomechanical Properties of Xenogenic 
Matrices
Clinical use of a tissue engineered valve, when developed using current approaches
to tissue valve engineering will have to take place within the context of the clinical
realities of valve replacement surgery and the limitations of tissue transplantation,
including the logistics of supply, preparation before surgery and availability of
appropriate sizes. At present methods used in the preparation of matrices can take as
long as one week [1] and such procedures while they can be planned before surgery
are not an option in semi-urgent or urgent cases in the clinical setting. The decellu-
larization protocol employed by us and described in chapter I, is five days in dura-
tion. It became clear to us that the practicality of such procedures might be problem-
atic in a clinical setting and that having readily available, preserved matrices would
be a more practical option. Consequently, we investigated the feasibility of cryopre-
serving matrices.
Although cryopreservation has been used for decades to preserve homografts [2] it is
known to result in tissue damage with necrotic changes, disrupted cellular ultra-
structure, damage to the extra-cellular matrix and loss of proteoglycans. However
the mechanical properties appeared to be preserved despite the histological changes
[3,4,5]. The studies in this chapter were consequently performed for two main rea-
sons.
Firstly, the effects of cryopreservation on xenogenic matrices have not been reported
previously and to check these effects on the matrices prepared using our protocol,
we examined proteoglycan and collagen content as well as the mechanical strength
of porcine matrices before and after cryopreservation. Are they still strong enough
after cryopreservation?
Secondly, the removal of cells and at least some of the soluble proteins from the tis-
sue by decellularization must result in some alteration in their properties. Neverthe-
less, mechanical studies performed on a-cellular porcine matrices using burst pres-
sure and uni-axial tests suggest that the material properties of the extra-cellular
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matrices approach those of native valves and hence are preserved [6-8]. Despite these
observations, there is no a priori reason why this should be so and these same studies
report histological findings in matrices that indicate high porosity and locally col-
lapsed microstructure in matrices. In this study we also evaluated the effects of the
decellularization process used by us on porcine matrices by comparing them to fresh
tissue since such treatment may also alter tissue material properties.
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Abstract
The clinical use of acellular biological valves as scaffolds in tissue valve engineering
would require them to be readily available. This study examines the feasibility of cry-
opreserving porcine aortic valve matrices for use in tissue valve engineering.
Matrices prepared using an enzymatic-detergent decellularization protocol were
examined before and after cryopreservation. The biochemical status of tissues were
evaluated by collagen and uronic acid (proteoglycan) determination and their
mechanical properties were determined using a burst test. The histological and
ultrastructural properties were evaluated by light and electron microscopy.
Cryopreservation did not significantly affect the collagen and uronic acid content of
aortic leaflet matrices. Histological and ultrastructural sections, however, confirmed
extensive disruption of the extracellular collagen matrix and inter-fibrillar proteogly-
can associations following cryopreservation. Although neither the breakage force
nor the maximum force at failure was significantly different in matrices before and
after cryopreservation, the strain observed in matrices was significantly higher after
cryopreservation.
To our knowledge this is the first study to investigate the effects of cryopreservation
on aortic valve matrices. Cryopreservation did not significantly alter the biochemical
properties of porcine aortic valve matrices. Nevertheless, cryopreservation had sig-
nificant adverse effects on the structural and mechanical properties of matrices. Cry-
opreserved matrices showed significantly higher strain when stressed compared to
non cryopreserved matrices. While, theoretically matrices are only expected to be
functional for a limited time until regenerated in vivo, further mechanical testing is
necessary to evaluate the effects of these changes on the durability of porcine aortic
valve matrices for use in tissue valve engineering.
Key Words: Porcine Aortic Valve Matrices, Cryopreservation, Biological Valve Matri-
ces, Tissue Engineering Matrices.
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1. Introduction
Tissue engineered cardiac valves offer a means of overcoming the many limitations
of contemporary cardiac valve prostheses. Currently available prosthetic cardiac
valves are of two types; (a) bioprosthetic valves, made from either animal or human
tissue and (b) mechanical valves made from non biological material. Mechanical
prosthetic valves, though very durable, require life long anticoagulation with its
associated risks [13, 46, 5, 26]. Bioprosthetic valves do not require life long anticoag-
ulation but their lack of living cells to replenish and maintain their tissue renders
them prone to early deterioration [15, 17] A tissue engineered living valve, would
replenish its extracellular matrix, avoid anticoagulation and theoretically offer the
possibility of growth after implantation.
One approach to tissue valve engineering involves seeding living cells onto an acellu-
lar biological matrix in vitro in order to produce a living construct before implanta-
tion. Acellular porcine aortic valves have been used by several groups as a biological
scaffold onto which living cells are seeded [42, 48, 43, 30, 6]. The clinical use of such
valves would require them to be available on short notice. However, before such a
valve can be implanted into a particular patient, currently available technology
would require the procurement of a suitably sized valve from an appropriately sized
animal and its subsequent decellularisation and quality control before being repop-
ulated with living cells. The efficiency of such a process would be greatly enhanced if
quality controlled matrices of several sizes were readily available and thereby alleviate
the need of matrix production each time a valve is required.
It is essential that any method employed to preserve matrices and to make them
available ‘off the shelf ’ do not significantly alter their properties. Several methods
including glutaraldehyde fixation, preservation in antibiotic solutions and cryop-
reservation are currently used to preserve heart valves. Cryopreservation has been
used for several years to preserve human allograft valves for use in aortic valve
replacement [28]. The aims of this study were to investigate the effects of cryopreser-
vation on the structural and biochemical properties of porcine aortic valves matri-
ces, as a means of having readily available, stored matrices for use in tissue valve engi-
neering.
Aortic valvular grafts are usually implanted as conduits and are comprised of the
aortic leaflets and associated aortic wall. While other studies in our laboratory are
focused on the aortic wall, in this study we report only the effects of cryopreserva-
tion on aortic leaflet matrices. The extra cellular leaflet matrix contain a variety of
structures and performs a variety of functions including mechanical support and
physical strength [34,25,37]. In addition it influences cellular adhesion, migration
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and gene expression following cellular contact [1,40]. Consequently the structural
and functional integrity of leaflet matrices are crucial to satisfactory valvular per-
formance.
At present, there is no standardized method of preparing valvular matrices for tissue
valve engineering. Cell lysis followed by enzymatic digestion and detergent extrac-
tion is commonly used to prepare acellular biological matrices [43] and for purposes
of this study, matrices were prepared using a patented detergent-enzymatic protocol
which has been successfully used and reported in the literature [45, 47].
Biochemical properties were evaluated by determination of the collagen and prote-
oglycan content in leaflets and structural properties by a standard burst test.
2. Methods
2.1 Valve Procurement
Porcine valves used in this study were obtained from the experimental slaughter
house of the University of Ghent, Department of Animal Production. Animals were
seven month old commercial slaughter pigs weighing approximately 110 kg each.
The genotype of all animals was a cross between a hybrid sow and piétrain boar (BL:
Belgian Land Race). The mean annular diameter of valves used was 23 mm. Immedi-
ately after slaughter, hearts were retrieved and placed on wet ice for transportation
to the Laboratory of Experimental Cardiac Surgery, University Hospital Ghent. Aor-
tic valves were dissected free as four centimetres long conduits with a two millime-
tres rim of myocardium.
Valves were procured on nine occasions depending on availability. Valves from each
procurement day were used to determine one or more parameters. As such for each
parameter valves from two or more procurement days were used. Although procure-
ment on different days was out of logistical necessity, it allowed minimization of
possible batch effects. The variability in the number of valves available on a particu-
lar day meant that the number of valves used to determine each parameter was not
always the same and in particular we had more valves available for testing as matrices
after cryopreservation.
Valves were processed whole and leaflets excised for analysis. Two hundred and
twenty six porcine aortic valve leaflets were studied. Sixty four leaflets were studied
fresh (collagen determination n=11, Uronic acid determination n=15, and mechani-
cal testing n=38), 98 were studied after decellularisation (collagen determination
n=15, uronic acid determination n= 15, and mechanical testing n= 68) and 64 matri-
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ces after cryopreservation (collagen determination n=13, uronic acid determination
n=20, and mechanical testing n=31).
Five additional valves were each divided into three parts, each comprising one leaflet
and its adjacent aortic wall, which were used for ultrastructural and histological
analysis. One part of each valve was examined fresh, while the other two were decel-
lularised to produce matrices, one of which was examined before and the other after
cryopreservation.
2.2 Decellularisation
Matrices were obtained using a detergent-enzymatic treatment as described by Wil-
son and co-workers [45] and Zeltinger and co workers [47]. Essentially tissues were
rinsed in hypotonic saline containing phenyl-methylsulfonylfluoride (PMSF: 1µM,
SIGMA, Bornem, Belgium) and antibiotics (streptomycin: 100µl/l; penicillin: 100µl/
l mixture; SIGMA, Bornem, Belgium). Cells were then ruptured by subjecting the tis-
sues to alternating treatments in hypotonic Tris-buffer (pH 8.0) and hypertonic Tri-
ton X solution (pH.8.0)(Biorad, Eke, Belgium). All solutions were supplemented
with PMSF (1µM) , penicillin/streptomycin solution (100µl/l respectively) and 50
µM butylated hydroxyanisole (SIGMA, Bornem, Belgium). After thorough rinsing,
tissues were subjected to a digestive procedure using an enzymatic solution contain-
ing Dnase1, RnaseA, trypsin and phospholipases A2, C, and D (SIGMA, Bornem,
Belgium). To ensure complete digestion we employed two enzymatic treatments of
45 minutes each. Tissues were then washed for 24 hours in a magnesium and cal-
cium free chelating solution. All steps were performed at 4°C.
2.3 Cryopreservation
Valves were cryopreserved according to the protocol of the tissue bank of the Univer-
sity Hospital, Ghent. Valves were placed into hanks balanced salt solution (HBBS,
Gibco, Belgium) supplemented with antibiotics and 15 % dimethyl sulfoxide
(Me2SO) (Merck, Darmstadt, Germany). Specimens were then cryopreserved by
freezing at a controlled rate of 1° C per minute down to a temperature of –80°C,
followed by a decrease of 10°C per minute to a temperature of –100°C. Valves were
subsequently stored in the vapour phase of liquid nitrogen at –196°C for a mini-
mum of two weeks before they were studied. Cryopreserved valves were gently
thawed, first in a 37°C warm water bath and rinsed alternately for four minutes in
each of three solutions of 250 ml of hanks balanced salt solution containing 26 ml,
13 ml and 6 ml DMSO respectively at room tempreature, before final rinsing in
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HBSS alone. Valves were inspected and found to be free from cracks or other gross
damage after thawing.
2.4 Collagen Determination
Total collagen was determined according to the protocol of The International Stand-
ards Organisation; ISO/DIS 3496.2 [21]. Essentially, dried (30 minutes at 103 °C)
porcine leaflets were hydrolysed using 6M HCl at 110°C for 24 hours. The released
hydroxyproline was determined after oxidation with chloramine-T, resulting in for-
mation of pyrrole-2-carboxylic acid and pyrrole. Pyrrole was determined using a col-
our reaction with Ehrlichs Reagent (p-dimetylaminobenzaldehyde) in perchloric
acid and isopropanol to give dipyrryl-phenylmethene salt and ms-tetra-(4-dimethyl-
aminophenyl)-porphin . The latter was read spectrophotometrically at 558 nm and
the percentage of collagen was calculated based on a standard curve using hydroxy-
proline solutions of known concentration ranging between 0.5 and 4 µg/ml sub-
jected to the same colour reaction and using a conversion factor of 8.
2.5 Histology and Ultrastructure
2.5.1 Electron Microscopy
Samples were fixed in phosphate buffered solution of 4% formaldehyde (Merck,
Darmstadt, Germany), supplemented with alcian blue to precipitate and preserve
the proteoglycans during the dehydration. Specimens were subsequently post fixed
with 1% osmium tetroxide (OsO4) in phosphate buffer (Merck, Darmstadt, Ger-
many) and embedded in epoxy resin. Ultra-thin 60nm sections were cut and exam-
ined with a Jeol 1200 EX-II transmission electron microscope at 80 keV (Jeol, Zaven-
tem, Belgium).
2.5.2 Light Microscopy
Samples for histology were fixed in 4% phosphate buffered formaldehyde (Merck,
Darmstadt, Germany) and embedded in paraffin. Five micron thick sections were
cut and stained with hematoxylin/eosin or with alcian blue and viewed by Axiovert S
100 light microscope (Axiovert S 100, Zeiss, Zaventem, Belgium).
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2.5.3 Uronic Acid Determination
Uronic acid content was used as an estimate of the amount of proteoglycan present
in matrices based on the methods described by Ahmed et al [1] and Blumenkrantz
and Asboe-Hansen [8]. Essentially, after freeze drying, samples were weighed and
then hydrolysed with 5ml of 2.5% sulphuric acid (H2SO4) in an autoclave at 121°C
for one hour. The hydrolysate was filtered and three aliquots of 0.6 ml each were
used for uronic acid determination. To each aliquot 3 ml of tetraborate solution
(0.0125M in concentrated H2SO4) was added and solutions were placed at 100°C for
five minutes. The colour reaction was developed by adding MHDP (0.15 % 2-
hydroxy-bifenyl in 0.15 % NaOH) solution to two aliquots. The third aliquot was
used as a blank in which 60 µl 0.5% NaOH was added instead of MHDP. Absorbance
was measured at 520 nm. Uronic acid was determined based on a standard curve of
glucuronic acid at concentrations ranging from 10 to 150 µg/ml.
2.5.4 Mechanical Testing
Whole leaflets were mechanically tested using a burst test similar to the standard-
ized burst tests ((ISO 3379 (1976-02), ASTM D 3786, ASTM 3787-01, DN EN 12332-
2(2003)) that are commonly used for flat flexible materials [10, 4, 22]. The analysis
employed a texture analyser TA500 (TM Lloyd Instruments, UK) interfaced to a com-
puter using the Nexigen 3.0 / Ondio software packages (TM Lloyds Instruments, UK)
which allowed electronic registration of data. Tissues were placed over an opening of
7 mm between two metal plate-clamps and secured using two pieces of water proof
sandpaper (Nr. P120) to prevent slipping. Force at a cross head speed of 100 mm/
minute was applied onto the leaflet until breakage by a polished ball tipped plunger
of 4.5 mm diameter (Fig.1). Care was taken to ensure that leaflets completely covered
the opening in the plates with the nodule of Arantius in the centre of the opening for
consistency. Leaflets were placed flatly onto the plates and kept taught until
clamped. All measurements were done at room temperature and tissues were kept
moist with isotonic salt solution. The stress/strain curves for all tissue tested were
obtained by conversion of the load/extension curves to stress/strain curves as
described in Appendix 1.
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Figure 1: Illustration of the plunger and clamped leaflets.
2.5.5 Statistics
All statistical analysis in this study was performed using student’s ‘t’ test. Differ-
ences with a p value <0.05 were taken to be significant. Mean values are expressed
with their corresponding standard deviations.
3. Results
3.1 Decellularisation, Histology and Ultrastructure
Fig. 2 (a, b, c) shows representative light microscopic preparations stained with
alcian blue of fresh porcine aortic valve leaflets and of matrices before and after cryo-
preservation. Matrices were almost completely acellular compared to fresh tissue. In
all three tissue types a collagenous matrix was observed. Proteoglycan staining by
alcian blue was more extensive in fresh tissue compared to both types of matrices.
The extent of alcian blue staining of proteoglycans in cryopreserved matrices did not
appear to be significantly different from that in non-cryopreserved matrices. Never-
theless, in histological preparations of matrices that were cryopreserved, there were
more areas of what appeared to be empty spaces, when compared to matrices that
were not cryopreserved.
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Figure 2. Representative light microscopic (a, b, c, Magnification X50; Alcian Blue Stain 
(Proteoglycans stain blue)) and electron microscopic (d ,e, f, Magnification X 2500) preparations 
of fresh porcine aortic valve leaflets and porcine aortic valve matrices before and after 
cryopreservation. Matrices (b and c) were acellular compared to fresh tissue (a) and showed less 
staining of proteoglycans. In d, e and f, the electron dense material represent precipitated 
proteoglycans (arrow head) and collagen is represented by the less electron dense linear structures 
(arrow).
a b c
d e
f
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Representative electron micrographs of all three types of tissue are shown in Fig. 2
(d, e, f). In fresh tissue, thick bundles of transversely and longitudinally sectioned
collagen fibers were observed with electron dense precipitates representative of pro-
teoglycans in between. Matrices that were not cryopreserved also showed longitudi-
nally and transversely cut collagen fibers. Unlike the fresh tissue, however, collagen
fibers appeared to have a looser association with each other and the extra-collagen-
ous matrix was less electron dense. Electron dense precipitates of proteoglycans
could still be seen bridging adjacent collagen fibers. In cryopreserved matrices, the
collagen fibers lost most of their striated appearance and indicated extensive disrup-
tion and destruction. Fibers were typically less densely packed and appeared loosely
associated compared to non cryopreserved matrices. Electron dense precipitates of
proteoglycans , although still present, appeared clumped and unlike fresh tissue and
non cryopreserved matrices did not seem to cross -link adjacent collagen fibers.
3.2 Biochemistry
Table 1 summarises the collagen and uronic acid content of fresh leaflets and of leaf-
let matrices before and after cryopreservation. The average collagen content in fresh
leaflets was 49%. In matrices that were not cryopreserved and cryopreserved matri-
ces, the average collagen content was 63.3% and 60.3% respectively, and were not sig-
nificantly different (p = 0.485).
Uronic acid content in fresh leaflets was 9.6 µg/mg dry weight. In matrices that were
not cryopreserved, and cryopreserved matrices, the uronic acid content was 2.8µg/
mg and 3.2 µg/mg dry weight respectively and these values were not significantly dif-
ferent (p=0.540).
3.3 Mechanical strength
Fig. 3a illustrates typical load/extension curves obtained for each type of tissue. The
typical curve obtained showed an initial extension followed by a transition to a steep
Table 1. Collagen content (%) and uronic acid content (µg/mg) expressed on dry material of fresh 
leaflets and matrices before and after cryopreservation (cryo).
Biochemical component
Fresh porcine 
leaflets
Matrices before 
cryopreservation
Matrices after 
cryopreservation
Collagen (%)
Valve leaflet 49.5a (11) 63.3b (15) 60.3b (13)
Uronic acids (µg/mg)
Valve leaflet 9.0a (6) 2.8 b (5) 3.2b (5)
a,b: values having different superscripts differ significantly between columns (p<0.05), ( ) = number of observations.
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rising phase with a slight reduction in slope before it peaks. The change in slope rep-
resents the point at which the tissue started to fail and is referred to as the breakage
force. The peak of the curve coincided with perforation of the leaflet and represented
the maximum force registered. The Failure phase (FP) of the curve was represented
by the duration from the commencement of failure (breakage force) to perforation
of the leaflet (Fig. 3b). Figure 4 (a, b, c) shows representative series of measurements
obtained for each type of tissue to maximum force. The breakage force was not sig-
nificantly different in the three types of tissue (Table 2). FP was more abrupt in fresh
leaflets and the average maximum force reached was significantly lower than in
matrices. Neither FP nor the average maximum force was significantly different in
matrices. Representative stress/strain curves for each type of tissue are illustrated in
Figure 5 (a, b, c). The strain at maximum force in matrices that were not cryopre-
served was not significantly different from that of fresh tissue. In cryopreserved
matrices, the strain at both the breakage force and the maximum force was signifi-
cantly higher compared to non cryopreserved matrices and fresh (Table 3).
Table 2. Average values of parameters derived from the load/extension curves resulting from the 
multiaxial test on fresh valve leaflets and valve matrices before and after cryopreservation.
Porcine valve Fresh
Matrix before 
cryopreservation
Matrix after 
cryopreservation
n 38 68 31
Maximum force (N) 17.9a 20.3b 21,1b
Breakage force (N) 17.5 18.6 19.1
Failure phase (mm) 0.11a 0.39b 0.43b
a,b: values having different superscripts differ significantly between columns (p<0.05), ( ) = standard deviation.
Table 3. Average values of parameters derived from the stress/strain curves as derived from the 
load/extension curves resulting from the multiaxial test on fresh valve leaflets and valve matrices 
before and after cryopreservation.
Fresh Porcine 
Leaflets
Matrix before 
cryopreservation
Matrix after 
cryopreservation
n 38 68 31
Strain (%) at
Breakage Force 49.7a (41.1) 54.3a (32.3) 73.2b (46.1)
Maximum Force 52.6a (41.1) 63.2a (36.3) 86.7b (55.4)
Stress (kPa) at
Breakage Force 310.4 (74.1) 322.7 (88.3) 300.0 (87.7)
Maximum Force 310.9 (74.6) 334.1 (82.3) 310.6 (89.8)
a,b: values having different superscripts differ significantly between columns (p<0.05), ( ) = standard deviation.
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Figure 3a. Representative load/extension curves for each type of tissue.
Figure 3b. Illustration of the failure phase (FP) on the load extension curves.
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c
Figures 4 (a,b,c). Representative series of load/extension curves for fresh tissue (a), matrices (b) 
and cryopreserved matrices (c), shown to maximum force
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a b
c
Figure 5 (a, b, c): Stress/strain curves as derived from the load/extension curves resulting from the 
multiaxial test on fresh tissue (a), matrices before cryopreservation (b) and matrices after 
cryopreservation (c).
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4. Discussion
The extracellular matrix of valvular leaflets is comprised of collagen, proteoglycans
and elastin organised into three distinct layers, namely the fibrosa , the ventricularis
and the spongiosa sandwiched between the latter two [38]. The main structural layer
is the fibrosa which is comprised mainly of multidirectional collagen with a smaller
amount of elastin [31]. Towards the belly of the leaflet, away from the free edge at
the point of force application as in this study, collagen fibers are increasingly multi-
directional [31]. The collagen fibers are surrounded by proteoglycans which is also
the major component of the spongiosa layer.
There was no significant change in total collagen content nor the amount of prote-
oglycans in matrices after cryopreservation. (Table 1). Yun Hee and Wolfinbarger
[47], who studied the effects of cryopreservation on proteoglycans in aortic tissue,
reported no loss of proteoglycans after cryopreservation and our findings in valvular
leaflet matrices is in keeping with these observations. The lower proteoglycan con-
tent in matrices compared to fresh tissue (p<0.005) is consistent with earlier reports
showing a loss of proteoglycans following decellularisation of porcine aortic valves
[36]. Collagen was determined as a proportional percentage of tissue dry weight.
Decellularization is known to result in a loss of dry weight of fresh aortic valve leaf-
lets [36]. This loss of material content with decellularisation could explain the
higher proportional collagen content observed in matrices compared to fresh tissue
(p<0.005). After cryopreservation, alcian blue stain did not show a difference in the
amount of proteoglycans present in cryopreserved and non cryopreserved matrices
and supported the quantitative findings.
The mechanical properties of heart valves, like similar connective tissue material, is
determined by a complex of forces including such relations as complementation
between elastin and collagen and proteoglycan-fibrillar interactions [7, 41]. The con-
sequences of such interactions results in specific anisotropic properties in tissues
such as aortic valve leaflets. In addition, it has also been suggested that heart valves
achieve their function partly as a result of a translational movement of the fibrosa
and ventricularis relative to each other resulting in an increase in valve surface area
during diastole [39]. Such movements involve considerable shear forces within the
leaflet and are believed too be facilitated by the proteoglycan rich spongiosa layer
between the fibrosa and ventricularis layers. Since this study focused on the proper-
ties of the leaflets as a whole, the burst test was preferred to uniaxial or biaxial test as
it allowed us to address both the contribution of the multidirectional collagen archi-
tecture without decoupling of fibers as is the case when strips of tissue are tested as
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in uniaxial tests [11] and the possible translational movements within leaflets
(appendices 2 and 3).
The breakage force was not significantly different between the three types of tissues.
In fresh tissue, however, the maximum force was significantly higher than in matri-
ces (table 2). The calculated strain was higher in matrices compared to fresh tissue
although not significantly different between fresh tissue and matrices that were not
cryopreserved (table 3). Cryopreserved matrices, however, exhibited significantly
higher strain at both the breakage force and maximum force compared to matrices
that were not cryopreserved.
Both a loss of proteoglycan and disruption of collagen fibers may contribute to
increased strain as the tissue is stressed to breakage. Inter-fibre proteoglycans can
play a significant role in tissue mechanics. When stressed, collagen fibers in aortic
leaflets have been shown to undergo extensive fiber rearrangement [32]. Loss of
inter-fibrillar proteoglycans could impede fiber realignment and prevent the even
redistribution of load in the test material with high strain in areas of higher stress,
thereby offering a possible explanation for the higher strain observed in matrices [9].
The latter implies that in fresh tissue with a higher proteoglycan content compared
to matrices, a more even distribution of force should prevail and consequently more
simultaneous failure of the tissue components. Indeed, we have observed more
abrupt failure in fresh tissue in which proteoglycan content was higher compared to
matrices (p= 0.001) (Fig 3a). The failure phase was more gradual in matrices and not
significantly different in duration (p= 0.646).
An important limitation of this study is that the mechanical test used did not allow
determination of the mode of failure of the tissue as in the case of uniaxial tests [33],
where the beginning of the failure is attributed to the commencement of breakage of
collagen fibers. Nevertheless, since it is well acknowledged that uni- and biaxial tests
do not adequately address the properties of anisotropic material [32, 20, 16, 19] and
since this study focused on the properties of the leaflet as a whole, the burst test was
preferred. While not providing a complete insight into the mode of failure it pro-
vided a measure of the bursting strength of the whole tissue at its weakest point.
It should be noted that while the majority of homografts currently implanted are
cryopreserved, alternative methods of allograft preservation include storage in nutri-
ent medium at 4°C which is also currently employed as well as earlier methods such
as vitrification and freeze drying. Cryopreserved homografts show excellent long
term clinical results [29]. Moreover, in addition to demonstrating that cryopreserva-
tion did not affect the collagen and proteoglycan extracellular matrix of allografts,
Aidulis et al recently demonstrated that vitrification using 2,3-butanediol with or
without polyethylene glycol followed by freezing in liquid nitrogen was impractical
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due to devitrification upon thawing, while freeze drying resulted in significant
mechanical damage to the allograft tissue [2]. In this study we investigated cryop-
reservation in light of the reported excellent clinical performance of cyopreserved
allografts. Nevertheless, satisfactory clinical results have also been reported with
homografts stored in antibiotic supplemented medium despite poorer preservation
of endothelial cells compared to cryopreservation [27, 24,23] and suggests storage in
antibiotic supplemented medium to be a viable alternative mode of preservation
warranting investigation. Investigation of the use of this technique for aortic valve
matrices however, was beyond the scope of the present study.
In conclusion: To our knowledge this is the first study to investigate the effects of
cryopreservation on aortic valve matrices. Neither collagen nor proteoglycan content
of porcine aortic valve matrices were significantly affected by cryopreservation. Cryo-
preservation, however, significantly affected the structural properties of porcine aor-
tic valve matrices. While the ultimate strength of the tissue was not significantly
affected, cryopreservation resulted in structural changes in the collagenous matrix
and significantly increased the strain in matrices when pressurised. It is known that
cryopreservation results in an alteration in the appearance of the histoarchitecture
of heart valve tissue and it has been suggested that damage caused by cryopreserva-
tion is most likely due to ice formation within highly hydrated proteoglycan- and
glycosaminoglycan-containing extracellular matrix [35]. Theoretically, in tissue valve
engineering, matrices are only expected to be functional for a limited time until
regenerated in vivo [45]. Determination of whether or not the increased strain
observed in cryopreserved matrices significantly affects matrix durability warrants
further investigations including tissue fatigue studies and in vivo testing.
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Appendix 1
Conversion of load/extension curves to stress/strain curves
Stess/strain curves were calculated as follows. Appendix 1 Fig. 1, illustrates the
dimensions used in the calculations.
Appendix 1 Fig. 1. Illustration of the dimensions used in the stress/strain calculations.
Using the XY-axes to base on the calculations
1. The equation of the circle is calculated with as coordinates of the midpoint: (3.5,
h-r)
2. Then the equation of the tangent at the circle trough the origin O is calculated,
and the slope m of this tangent is then found.
3. Then the coordinates of the point of contact (Xa, Ya) are calculated.
4. Based on these data, the mantle-area of the truncated cone OABD can be calcula-
ted: [= ½ AO × (periphery of the circle AB + periphery of the circle OD)]
5. Also the area of the upper part ACB of the sphere can be calculated (2πrh2).
6. The sum of these 2 areas (truncated cone + the part ACB of the sphere) = the area
of the (expanded) valve during the test.
7. Based on the calculated area of the valve, the stress and % strain can be calculated
at each point of a load/deformation curve: stress = load (N) / area valve expres-
sed as kPa; and % strain = (area valve – area opening in the plates) / area ope-
ning in the plates x 100.
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Formulae used in the calculations
1. Slope of the tangent at the circle trough the origin O:
2. Coordinates of the point of contact (point A):
    and    
3. Mantle-area of the truncated cone OABD:
4. The area of the upper part ACB of the sphere:
5. Stress (kPa) at a certain point in the curve:
6. Strain (%) at a certain point of the curve:
Calculations were based on a value of 4.5 mm diameter of the sphere, and a diameter
of 7 mm of the whole in the plates. In the calculations, friction due to the polished
ball is assumed to be negligible.
Appendix 2
Appendix 2 Fig. 1, illustrates the burst test as opposed to a uniaxial or biaxial test.
Heart valve leaflets are know to be anisotropic with a multidirectional collagen
architecture and especially so in the central portion of the leaflets as tested. Gener-
ally the burst strength (BS) is proportional to the tensile strength (Force (N)) and
square root of strain (εmax) to failure (BS ∝ F √ εmax), with a correction factor being
applied to correct for the effect of fibre properties such as length and thickness [12].
As the plunger presses downwards, the leaflet is subjected to a complex of forces
including radial, lateral and shear forces. Fibers lying under the plunger will experi-
ence mainly axial forces while those lateral to the plunger will experience mainly lat-
eral forces (Appendix 2 Fig. 2). In all areas adhesion between fibers (extra-collagen-
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ous matrix) will impact on the mechanical behaviour and ultimate burst strength of
leaflets by affecting fibre realignment.
Appendix 2 Fig. 1. Illustration of the burst pressure as opposed to a uniaxial 
and a biaxial test set up.
Appendix 2 Fig. 2. Axial and lateral forces applied to the collagen fibers during mechanical testing.
Appendix 3
The ability of the different layers of the aortic valve to slide relative to each other
when pressurised is well known. Such mechanical behaviour increases the load bear-
ing ability of the tissue by reducing the magnitude of peak tensions developed as lay-
ers slide relative to each other [14]. As force is applied (Appendix 3 Fig. 1), elongation
(El) of fibers in the clamping area (area I) is dependent on α1 and d (where α1 = bend-
ing angle, and d is a function of sample thickness, geometrical parameters of the
device and depth of the plunger) and can be calculated from the relationship El = α1 x
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r (r = radius of the arc depicted by α1 and the fibre being considered). As such the
uppermost fibers will experience maximum elongation and the lowest fibers little or
no elongation. In the area of force application (area III), the converse is true when
one considers the arc described by the bending angle α2. In this area the lowest fibers
will experience more elongation than the uppermost fibers. In area II, the pattern of
elongation lies in between that of areas I and III. The opposing patterns of elonga-
tion between fibers in the upper and lower layers of the leaflet will result in consider-
able shear forces being developed within the tissue by translational movement of the
upper and lower layers.
Appendix 3 Fig 1. Illustration of the influence of the applied force on the elongation of fibers 
depending on the valve leaflet area.
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Part III
Heart valve leaflets are coated with a layer of endothelial cells which may be geneti-
cally different from endothelial cell from other sites, but the extent and nature of
these differences are not known [1]. Indeed an interesting observation in this regard,
is that in experimental heart transplantation with massive myocardial rejection, lit-
tle inflammation is observed in the valves [2].
Earlier studies performed by Filip and co-workers [3] suggested that interstitial cells
of heart valves possess morphological and functional characteristics similar to
smooth muscle cells. These authors showed that valvular interstitial cells, like
fibroblasts were devoid of basal lamina, have long thin cytoplasmic extensions and
were intimately associated with the extra-cellular matrix. Characteristically, they pos-
sessed well developed rough endoplasmic reticulum and Golgi apparatus and are
extremely rich in micro and intermediate filaments. Like smooth muscle cells they
were coupled by communicating (gap) junctions, contained actin filaments and
dense bodies, expressed cGMP-dependent protein kinase and were closely apposed
to motor nerve terminals. Moreover, they were capable of contraction in vitro. More
recently, Taylor and co-workers [4] demonstrated and confirmed that valvular inter-
stitial cells comprised a heterogenous cell population whose major phenotype was
that of myofibroblasts. Valvular interstitial cells are believed to continuously synthe-
size, remodel and replenish the connective tissue matrix [5].
The origins of valvular interstitial cells and their replenishment are not fully under-
stood. Evidence [6,7] suggest that the principal source of cells in both the fetus and
adults is the overlying endocardium, whereby cells undergo an epithelial to mesen-
chymal transformation and migrate into the matrix. Cells from two other extra-car-
diac sources are also found in developing valves, namely epicardial cells and neural
crest cells. There is also evidence suggesting that the epithelial-mesenchymal trans-
formation continues post-natal [8].
Several authors have reported on the use of interstitial cell isolates to seed matrices
in heart valve engineering [9-11]. These isolates were invariably obtained from vascu-
lar cells. To date, a functional tissue engineered valve has not been developed and the
density of cells needed to achieve repopulation of a matrix, with current technology,
is unknown. In preliminary evaluations of vascular interstitial cells we established
that these cell populations were not made up purely of myofibroblast. Hence we
report in this chapter, a model to procure myofibroblasts in large quantities for cell
seeding by transdifferentiating fibroblasts in interstitial cell isolates using Trans-
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forming Growth Factor-β1. In addition to vascular interstitial cells we investigated
the transdifferentiation of dermal mesenchymal cells since the procurement of these
cells involves less invasive methods compared to vascular cells.
Investigations to seed matrices in our laboratory, which are still underway, revealed
that after transdifferentiation, myofibroblasts did not sufficiently proliferate within
the matrices after apparent invasion. It has been shown that the biological responses
of proliferation and transdifferentiation were mutually exclusive events in fibrob-
lasts and that these responses to TGF-B1 are regulated via a CTGF-dependent path-
way in concert with either EGF or IGF-2 [12]. Consequently, under TGF- B1 stimula-
tion the cells will either proliferate or differentiate. We hypothesized that the myofi-
broblasts in our seeding experiments were transdifferentiating at the expense of
proliferation. In the second part of this chapter we establish a cocktail of growth fac-
tors including TGF-β1, to overcome TGF-β1 imparted inhibition of proliferation of
fibroblasts and to promote their invasion, namely bFGF, EGF and TGF-β1.
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Part IV
In Vivo Evaluation of Kangaroo and Porcine 
Xenogenic Scaffolds
In attempts to tissue engineer a functional aortic valve, matrices are currently
implanted either after in vitro seeding of cells or un-seeded with expected repopula-
tion in vivo. Most commonly, scaffolds are seeded with vascular interstitial cells.
However, the parameters necessary to establish a pheno-typically appropriate cell
population and density distribution are not fully defined [1]. As such whether a
valve is sufficiently repopulated in vitro to regenerate the template scaffold is diffi-
cult to establish, as is the length of time necessary to accomplish the requisite repop-
ulation. To date reports of implantation of matrices in sheep either seeded with cells
prior to implantation or un-seeded with expected repopulation in vivo, have shown
that matrices failed to repopulated and instead elicited a foreign body reaction [2].
Implanted matrices are expected to remain vital, be regenerated and thus not calcify.
Such regeneration is not instantaneous and would require time to accomplish. If
implanted un-seeded regeneration will have to await repopulation in vivo. Whether
or not such a tissue engineered valve will be sufficiently endowed to prevent calcifi-
cation of its components in this time frame is unknown. In fact, in light of the
reported foreign body reaction this does not seem to be the case. Matrices exposed to
the immune system can elicit a foreign body reaction and calcify. Current
approaches to overcome these obstacles include attempts to seed xenogenic scaffolds
with autologous endothelial cells and thus shield them from the host’s immune sys-
tem. However it is known that complete covering of the scaffolds by endothelial cells
can be variably complete and cannot be guaranteed. As in the case of bioprosthetic
valves, other factors such as mechanical fatigue might be expected to contribute to
the calcification of the scaffold as long as it is not renewed. Consequently, the calcifi-
cation potential of matrices can have a significant impact. In this chapter we
describe the evaluation of the calcification potential of both kangaroo and porcine
a-cellular and non endotheliazed matrices in sheep compared to a contemporary
bioprosthesis in order to assess the severity of this problem.
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Abstract
Currently available bioprosthetic heart valves have a limited durability whereas their
more durable mechanical counterparts require anticoagulant therapy. An engi-
neered aortic valve would theoretically be capable of growth and like a normal native
aortic valve it would maintain its durability by regenerating its extracellular matrix
and require no anticoagulation therapy in recipients. A major limitation of currently
available bioprosthetic valves is their propensity to calcify. At present, one approach
to tissue engineering uses decellularized, xenogenic scaffolds that are implanted,
either after in vitro seeding of cells or unseeded, with the expectation of complete
matrix repopulation in vivo. Whether or not such a tissue engineered valve will be
sufficiently endowed to prevent calcification of its components is unknown and as
such the inherent calcification potential of the scaffold can be a significant determi-
nant of its durability. This study examines the calcification potential of xenogenic
biological scaffolds from two species, namely pigs (n=3) and kangaroos (n=3) in the
sheep model and compared them to a commercially available glutaraldehyde treated
porcine bioprosthetic valve (Toronto SPV®) which is a routinely used valve (n=3).
Valves and matrices were explanted after 120 days, examined histologically (H&E
and Von Kossa stain) and electron microscopically and their calcium content deter-
mined quantitatively by Inductively Coupled Plasma Optical Emission Spectrome-
try. Mean calcium content in milligram per gram of dry weight (mg/g-dw) of
Toronto SPV valves was 2.63 mg/g-dw compared to 105.08 mg/g-dw in porcine and
43.81mg/g-dw in kangaroo matrices. Calcific deposits were located between as well
as in close association with fibers of the collagen matrix in all tissue. Toronto SPV®
valves calcified significantly less than the tested biological matrices irrespective of
species of origin. Xenogenic scaffolds are inherently prone to calcification with a
possible immune component.
Key Words
Kangaroo Aortic Valve Scaffold, Porcine Aortic Valve Scaffold, Toronto SPV Valves,
Aortic Scaffold Calcification.
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Introduction
The application of tissue engineering to cardiac valves attempts to produce a living
organ comparable to the native valve both structurally and functionally and is a
promising option in the treatment of aortic valve disease. An engineered aortic valve,
for instance, would be capable of growth and like normal native aortic valves it
would maintain its durability by regenerating its extracellular matrix and require no
anticoagulation therapy in recipients. At present, two types of prosthetic heart valves
are available, namely, bioprosthetic valves made from biological material and
mechanical valves made from non biological material. Both types of devices are asso-
ciated with significant limitations including a need for anticoagulation and degener-
ation [1-6]. Bioprosthetic valves include human homografts, and valves produced
from either bovine pericardium or porcine aortic valves. Homografts are usually cry-
opreserved before use, while the latter two are usually chemically cross-linked using
low concentrations glutaraldehyde [7]. Glutaraldehyde treatment of porcine aortic
valves for human implantation was first introduced in 1969 [8] and the majority of
bioprosthetic valves implanted currently are covalently cross-linked with glutaralde-
hyde. The Toronto SPV valve represents the latest generation of glutaraldehyde
treated bioprosthetic heart valves manufactured from porcine aortic valves. Unlike
mechanical prosthetic valves which have life long durability, bioprostheses do not
require life long anticoagulation, but are limited in their durability. The limited
durability of glutaraldehyde fixed bioprosthetic valves has been attributed to altered
mechanical properties, antigenic properties of the cells, glutaraldehyde interactions
and the calcification potential of cell membrane [9, 10, 11, 12].
Current approaches to tissue valve engineering include both the use of decellularized
porcine xenogenic tissue and bioresorbable synthetic scaffolds [13] which are either
seeded with cells in vitro before implantation or implanted unseeded, with expected
in vivo repopulation by host cells [13, 14]. Acellular biological matrices are devoid of
cells and theoretically do not harbour the potential of calcification due to cellular
material as do currently available bioprosthetic valves. Moreover, acellular matrices,
if not treated with glutaraldehyde would avoid glutaraldehyde interactions impli-
cated in calcification.
Tissue engineered heart valves constructed from xenogenic tissue have already been
implanted in humans [14, 15]. The results of these clinical implants however, have
been catastrophic for patients due to valve failure and emphasizes the need to fully
understand the pattern of failure of these constructs. [13, 15, 16].
In presently used bioprosthetic valves, calcific deterioration is a major cause of valve
failure [17, 18]. While a functional tissue engineered valve is expected to remain vital
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and regenerate its matrix and thus not calcify, such regeneration is not instantane-
ous and would require time to be fully accomplished in vivo. In this time frame, the
intrinsic calcification potential of xenogenic scaffolds could significantly influence
the construct’s calcification and hence its ultimate durability.
Current bioprosthetic valves have a life span of 15 to 20 years with negligible early
complications. Their pattern of failure is well established, highly predictable and can
be managed. The clinical feasibility of any tissue engineered valve will ultimately
have to be judged against these criteria [19, 20].
Glutaraldehyde treated kangaroo aortic valves have been shown by us as well as oth-
ers to have a calcification potential that is comparable to, if not lower than that of
porcine aortic valves [21, 22]. More recently, we have reported on the hydrodynamic
evaluation of kangaroo acellular matrices which suggests superior hydrodynamic
properties compared to porcine matrices [23]. Consequently, kangaroo aortic valves
might be considered a potential alternative source of acellular matrices for tissue
valve engineering.
The aim of this study was to compare the inherent calcification potential of xeno-
genic matrices from two species, namely kangaroo and pigs, to that of a routinely
used glutaraldehyde treated porcine bioprostheses, the TorontoSPV valve.
1. Materials and Methods
1.1 Valve Procurement and Scaffold Preparation
Three Toronto SPV valves of 21mm internal diameter used in this study were gener-
ously donated by ST. Jude Medical Corporation (St. Jude Medical, St. Paul, MN,
USA). Porcine valves were obtained from the experimental slaughter house of the
Department of Animal Production, Ghent University. The genotype of all animals
was a cross between a hybrid sow and piétrain boar. Immediately after slaughter,
hearts were retrieved and placed on wet ice for transportation to the Laboratory of
Experimental Cardiac Surgery, University Hospital Ghent. Aortic valves were dis-
sected free as four centimeter long conduits with a two millimeter rim of myocar-
dium and stored in a cold preserving solution of isotonic saline as described below.
Aortic valves were obtained from Eastern Gray Kangaroos (Macropus Giganteus)
under licence in Queensland, Australia. Valves were procured at the Queensland
Heart Valve Bank, University of Queensland, under similar conditions. Two addi-
tional decellularized valves of each type (kangaroo and porcine) were used to check
the effectiveness of the decellularization procedure. A non-decellularized porcine
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aortic valve was used to illustrate the relative cellularity of leaflets in porcine valves
used in the manufacture of bioprostheses and for histological illustration of calcium
in an unimplanted porcine leaflet. It should be emphasized that financial con-
straints precluded the use of Toronto SPV leaflets for the preimplant H&E and Von
Kossa stainig. Hence, for purely illustrative purposes non-decellularized native por-
cine leaflets were used.
While there is no universally standardized decellularization method, acellular matri-
ces are typically prepared by cell lysis in hyper- and hypotonic solutions, with subse-
quent enzymatic digestion and detergent extraction [13, 24]. For purposes of this
study, matrices were prepared using a patented detergent-enzymatic protocol which
has been successfully used and reported in the literature by us and others [23, 24, 25,
26].
Essentially tissues were rinsed in hypotonic saline containing phenyl-methylsulfo-
nylfluoride (PMSF: 1µM, SIGMA, Bornem) and antibiotics (streptomycin: 100µl/l;
penicillin: 100µl/l mixture; SIGMA, Bornem, Belgium). Cells were then ruptured by
subjecting the tissues to alternating treatments in hypotonic Tris-buffer (pH 8.0)
and hypertonic Triton X solution (pH.8.0)(Biorad, Eke, Belgium). All solutions were
supplemented with PMSF (1µM), penicillin/streptomycin solution (100µl/l respec-
tively) and 50 µM butylated hydroxyanisole (SIGMA, Bornem, Belgium). After thor-
ough rinsing, tissues were subjected to a digestive procedure using an enzymatic
solution containing Dnase1, RnaseA, trypsin and phospholipases A2, C, and D
(SIGMA, Bornem, Belgium). All steps were performed at 4°C.
1.2 Implantation and Explantation of Valve and Matrices
The study was approved by the ethical commission for animal experiments, Ghent
University. All animals received humane care in compliance with the Guide for the
Care and Use of Laboratory Animals, published by the National Institutes of Health
NIH (publication No.85-23, revised 1985). Nine juvenile, suffolk sheep used in this
study were obtained from a licenced supplier in Belgium.
The anaesthetic and operative procedure employed during right sided heart bypass
and pulmonary valve implantation in sheep has been reported by us in detail else-
where [27]. In short, the sheep were premedicated intravenously with 0.1 mg/kg
midazolam (Dormicum®, N.V. Roche S.A., Brussels, Belgium) and 0.1 mg/kg metha-
done (Mephenon®, N.V. Demolin S.A., Brussels, Belgium). Anaesthesia was induced
with 2-4 mg/kg propofol (Diprivan®, Astra Zeneca, Destelbergen, Belgium) and
maintained with isoflurane (Isoflo®, Abbott Laboratories Ltd., Queenborough,
Kent, United Kingdom) in oxygen, combined with infusions of propofol and fenta-
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nyl (Fentanyl-Janssen®, Janssen-Cilag, Berchem, Belgium). The heart was exposed by
a left anterolateral thoracotomy via the third intercostal space. Systemic anticoagu-
lation was induced with 3 mg/kg heparin (Heparine Leo®, Leo Pharma N.V./S.A.,
Zaventem, Belgium). Right heart bypass was established by pulmonary and right
atrial cannulation. The heart was kept normothermic and beating throughout the
procedure. The pulmonary artery was clamped, transected and the test valves and
matrices were interposed in the pulmonary trunk using running Proline 5.0 sutures
(Eticon , Merelbeke, Belgium) distally and proximally. Through a separate, lower
incision in the pulmonary artery, the native pulmonary valve was rendered incompe-
tent by destruction of its leaflets. Animals were weaned from bypass and heparine
was neutralised with 3 mg/kg protamine. An intercostal block using 0.5 % bupi-
vacaine (+ epinephrine) (Marcaine®, Astra Pharmaceuticals N.V./S.A., Brussels, Bel-
gium) was installed before closing the chest with a temporary thorax drainage sys-
tem in place. Post operatively and during the first three post operative days, analge-
sics included 0,1 mg/kg methadone IM every four hours during daytime and 0,01
mg/kg buprenorphine IM (Temgesic®, Schering-Plough N.V./S.A., Brussels, Bel-
gium) in the evening. Animals were euthanized after 120 days with an intravenous
bolus of 50 mg/kg pentobarbital (Natriumpentobarbital®, Kela N.V., Hoogstraten,
Belgium) and the valves explanted.
All animals received humane care in compliance with the Guide for the Care and Use
of Laboratory Animals, published by the National Institutes of Health NIH (publica-
tion No.85-23, revised 1985).
1.3 Explant Analysis
(a) Light Microscopy
Samples for histology were fixed in 4% phosphate buffered formaldehyde (Merck,
Darmstadt, Germany) and embedded in paraffin. Five micron thick sections were
cut and stained for calcium (Ca) with Von Kossa stain.
(b) Electron Microscopy
Samples were fixed in phosphate buffered solution of 4% formaldehyde (Merck,
Darmstadt, Germany), supplemented with alcian blue to precipitate and preserve
proteoglycans during the dehydration. Specimens were subsequently post fixed with
1% osmium tetroxide (OsO4) in phosphate buffer (Merck, Darmstadt, Germany) and
embedded in epoxy resin. Ultra-thin 60nm sections were cut and examined with a
Jeol 1200 EX-II transmission electron microscope at 80 keV.
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(c) Calcium content.
Samples were lyophylized and subsequently mineralized by ashing during 3 hours at
450 °C. Ashes were dissolved in six molar boiling nitric acid (Merck, Darmstadt, Ger-
many) and Ca was estimated spectrometrically using ICP-OES (Inductively Coupled
Plasma Optical Emission Spectrometry (Varian, Mulgrave, Victoria, Australia). Cal-
cium content is expressed as milligram per gram of tissue dry weight (mg/g-dw).
2. Results
Figure 1 illustrates a Toronto SPV® valve and kangaroo and porcine aortic matrices
that were implanted. Hematoxylin-Eosin (H&E) stained histological preparations
confirmed the decellularization of the kangaroo and porcine matrices as illustrated
in figure 2a and 2b. The relative cellularity of a non decellularized porcine aortic
valves representative of valves used to manufacture glutaraldehyde treated porcine
bioprosthesis, is illustrated in fig 2c. Kangaroo and porcine aortic matrices were ren-
dered completely acellular following the decellularization procedure. Figure 3 illus-
trates an acellular matrix (kangaroo) implanted in the pulmonary position of the
right ventricular outflow tract in a sheep. All explants showed some fibrous over
growth extending from the left ventricle towards the leaflets.
Fig. 1. Illustration of a Toronto SPV bioprosthese and Kangaroo (K) and Porcine (P) matrices used 
in this study.
a b c
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Fig. 2. H&E stain of porcine (a) and kangaroo (b) matrices and a native porcine aortic leaflet 
representative of that used in preparation of the Toronto SPV valve (c). Note the absence of cells 
in the matrices.
Fig. 3. An implanted matrix in the pulmonary position of the right ventricular outflow tract 
in sheep.
2.1 Von Kossa Stain
Figure 4 shows the von Kossa stain of explanted leaflets as well as of unimplanted
matrices. Leaflets from the Toronto SPV valves showed significantly less staining
compared to either type of matrix. Kangaroo matrices stained less intensely com-
pared to porcine matrices. In the Toronto SPV explants, calcium deposits appeared
to follow the distribution of cells and also occurred in larger isolated deposits. In
matrices, calcific deposits were located through out the leaflet and particularly at the
free edges.
a b c
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Fig. 4. Von Kossa stain for calcium in explants: (a)Toronto SPV valve, (b) porcine matrix and 
(c) kangaroo matrix. Note the Von Kossa staining of unimplanted porcine valve (d) and kangaroo 
(e) and porcine (f) matrices.
2.2 Electron Microscopy
Electron microscopic sections of explants are illustrated in Fig.5. Calcific deposits
were observed in all valves and matrices. In the Toronto SPV bioprostheses, calcifica-
tion appeared to be associated with cells and showed a diffuse distribution. In the
acellular matrices the calcific deposits were distributed throughout the leaflet in
close association with the collagen matrix. In areas where larger deposits of calcium
were found they were located between and in association with the collagen fibers. In
one preparation in which elastin was observed in an acellular porcine matrix, calcific
deposits were also strongly associated with the elastin fibers (Fig. 5C).
a b c
d e f
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Figure 5. Electron microscopic sections of explants at high and low magnifications indicated by bar: 
Toronto SPV valve (A and B), Porcine matrix (C and D) and Kangaroo matrix (E and F). In C the 
dark structure represents elastin fibers.
2.3 Quantitative Calcium Determination
Table 1 shows the raw data and Fig. 6 illustrates the mean calcium content in milli-
gram per gram of dry weight (mg/g-dw) for each type of tissue. The mean calcium
content in Toronto SPV was lower (2.63mg/g-dw) compared to either kangaroo
(43.8mg/g-dw, with p= 0.066) or porcine(105.8 mg/g-dw, with p= 0.001) acellular
matrices. Statistical analysis was done using the student’s t-test, with a value of
p<0.05 taken to be significant. Although the significance of the p value for compari-
son of means between the Toronto SPV and porcine matrices appear borderline,
bearing in mind that the limited number of observations due to the small sample do
not justify a normal distribution in the groups, it was clearly convincing.
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Figure 6. Average calcium content in milligram per gram of dry weight (mg/g-dw) 
for each type of tissue.
3. Discussion
The most significant finding of this study is that xenogenic matrices calcified signif-
icantly more than the Toronto SPV valve, a routinely implanted glutaraldehyde
treated porcine bioprosthesis, regardless of whether such matrices were derived from
porcine or kangaroo aortic valves. To our knowledge this is the first study to com-
pare the calcification potential of two xenogenic scaffolds to that of a routinely used
porcine bioprostheses in the sheep circulatory model.
We have previously reported the histological appearance of non-decellularized kan-
garoo and porcine aortic leaflet [21]. The light microscopic examination of both
types of xenogenic matrices in this study confirmed the effectiveness of the decellu-
larization procedure. Kangaroo and porcine matrices were rendered completely acel-
lular.
Several factors have been implicated in the calcification of glutaraldehyde treated
porcine bioprosthetic valves. In children, in whom bioprosthetic valve failure is
Table 1. Raw data of calcium content (Ca) in the different tissues. K= kangaroo, P= porcine, mg/g-
dw = milligram/gram dry weight,Sd = standard deviation
Tissue Sample Ca (mg/g-dw)
Mean Ca 
(mg/g-dw)
Sd
Toronto SPV 1
2
3
2.8
2.29
2.79
2.63 0.292
K-Matrix 1
2
3
76.20
32.47
22.74
43.81 29.474
P-Matrix 1
2
3
79.76
116.92
118.57
105.08 21.946
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observed more commonly than in adults a possible involvement of high serum phos-
phate and osteocalcin as well as enhanced metabolism of parathyroid hormone and
vitamin D has been suggested [28, 29, 30]. Both the cellular component as well as
glutaraldehyde treatment have been implicated in the pathological calcification in
these prosthetic valves.
In the present study, we observed deposits of calcium in close association with the
devitalized connective tissue cells as well as in close association with collagen and
elastin fibers. Indeed phospholipids and phosphoserine containing proteins have
been found in pathologically calcified tissue and products of cellular degradation
appeared to be the early sites of calcification [31]. These observations confirm previ-
ous ultrastructural findings in explanted valves which implicated valvular cells in
the calcification process [32].
While it is widely acknowledged that glutaraldehyde treatment results in a reduction
of immunological recognition of the xenogenic tissue and its stabilization to degra-
dative enzymes in humans [33], glutaraldehyde has been suggested to be a cause of
pathological calcification [9, 34]. In bioprosthetic valves, glutaraldehyde introduces
thermally and chemically stable cross-links which become compromised with time
and result in a leaching out of glutaraldehyde [35]. Such free aldehydes have been
shown to be easily oxidized to carboxylic acid which is a potential site for calcium
binding [36, 37]. Glutaraldehyde also stiffens and alters the biomechanical charac-
teristics of porcine valvular tissue. Such alterations are associated with demonstrable
changes in leaflet motion which produce abnormal stress patterns causing buckling,
accelerated calcification and eventual tissue failure [38]. In addition, glutaraldehyde
cross-linked valves are and remain non viable tissues, without opportunity for either
tissue renewal or growth which is explained by glutaraldehyde cytotoxicity and the
inability of cells to penetrate the cross-linked matrix [35, 39]. Furthermore, although
stable cross-links in cellular and extracellular matrix proteins are considered to
reduce immunogenicity, porcine tissue retains a residual ability to trigger an
immune response that can activate macrophages, which in turn can obtain an oste-
oblast calcium depositing phenotype [40]. Moreover, it is well established that cell
and the cellular membrane provoke early calcification of biological heart valves,
whereby a direct relation between specific antibody response and the calcification of
porcine tissue has been demonstrated [12, 41].
Acellular xenogenic matrices such as those tested in this study are devoid of cells and
are not treated with glutaraldehyde. As such these constructs might be expected to
calcify less than a glutaraldehyde treated porcine bioprostheses such as the Toronto
SPV valve. On the contrary, xenogenic matrices in this study demonstrated a greater
propensity to calcify and suggest that their preparation by decellularization and
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omission of glutaraldehyde treatment is insufficient to completely mitigate calcifi-
cation.
Xenogenic scaffolds are known to be more proinflammatory when cells are dis-
rupted and cell debris, cytokines, and other inflammatory moieties are not thor-
oughly removed from the matrix [42]. Recently, Reider et al. elegantly demonstrated
residual immunogenicity in porcine xenogenic scaffolds which resulted in a greater
stimulation of macrophage response compared to decellularized human aortic
valves in an in vitro assay using the migratory response of U-937 cells, a human
monoblastic cell line [43]. Indeed a failed tissue engineered porcine scaffold which
was implanted in humans with catastrophic results and has been subsequently with-
drawn from the market has been shown to possess gal-α 1,3 isotope, the major xenoan-
tigen(s) recognised in pigs by human natural antibodies [15, 44]. In the latter studies
an inflammatory macrophage and neutrophil granulocyte infiltration was reported
in the explants. Also, studies on human homografts, have shown that calcification in
these valves is related to a persistent immunoreactivity against donor antigens [45].
As such, in xenogenic scaffolds, regardless of their species of origin, in which immu-
nogenic moites persist, it is highly probable that the observed calcification in xeno-
genic matrices might be a manifestation of an immune response. Current
approaches to tissue valve engineering include attempts to overcome these obstacles
by seeding xenogenic or allogenic scaffolds with autologous endothelial cells before
implantation and thus shielding them from the host’s immune system. However it is
known that complete covering of the scaffolds by endothelial cells can be variably
complete and cannot be guaranteed [47].
It should be emphasized that while xenogenic scaffolds did calcify more than
Toronto SPV valves, there was a difference in the observed calcification in matrices
themselves. Kangaroo matrices calcified less than porcine matrices. As discussed
above, several factors have been implicated in tissue valve calcification. We have pre-
viously shown that kangaroo aortic valves differ histologically and hydrodynami-
cally from porcine aortic valves [21, 23]. It is highly conceivable that interspecies dif-
ferences may contribute to the observed differences in calcification of xenogenic
matrices. Further investigation of the differences between kangaroo and porcine
matrices is as such warranted. While such investigations were beyond the scope of
the present study, current research in our laboratory is also addressing this issue.
In conclusion, Xenogenic scaffolds calcify more than the glutaraldehyde treated
Toronto SPV® porcine bioprosthetic valve despite their decellularization and the
absence of glutaraldehyde treatment. Tissue engineered scaffolds will need to out
perform current bioprostheses in their calcification potential in order to take their
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place in the treatment of heart valve disease. The immunogenicity of such scaffolds
might help to explain their calcification and further research into rendering matri-
ces immunologically inert is warranted. Further research at our laboratory is dedi-
cated to improving biological scaffolds as well as fully characterizing associated
fibrotic development.
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General Discussion
The aim of this study was to initiate a research programme in the tissue engineering
of a functional aortic valve by addressing several fundamental issues considered crit-
ical in heart valve engineering.
This study demonstrated that a-cellular biological scaffolds can be prepared from
biological valves using a contemporary decellularization procedure and confirmed
similar reports in the literature [1,2]. Decellularization by definition alters the mate-
rial properties of the matrix and may weaken tissues. Such effects were evaluated and
suggest that the procedure employed did not significantly alter the mechanical
strength of the tissue but significantly reduced their proteoglycan content.
Although these results are in keeping with the literature it should be cautioned that
decellularization results in significant histological changes whereby tissues become
highly porous and exhibit locally collapsed microstructure [3,4]. The effects of these
changes might not always be appropriately reflected by present methods of testing.
The use of porcine xenogenic scaffolds currently dominates investigations in tissue
valve engineering. In this study we opted for biological matrices, for although poly-
mer based scaffolds are attractive from an engineering perspective in that they can be
created in a variety of shapes and sizes, they will still need to replicate the perform-
ance characteristics of the native aortic valve. Moreover they must successfully with-
stand the inevitable foreign body response after implantation. Biological scaffolds
are structurally and morphologically more similar to the native aortic valve and
eliminate the design difficulties faced by a polymer scaffold.
In this study we have introduced a novel biological scaffold for use in tissue valve
engineering, namely kangaroo xenogenic matrices. Kangaroo aortic valves differ his-
tologically and morphologically from porcine valves. Importantly they do not have a
rim of muscle in the right coronary cusp as is the case in porcine valves and they are
thinner than porcine valves [5,6]. A muscular bar can be obstructive to the flow of
blood through a valve. We have presented hydrodynamic finding in this study show-
ing that the effective orifice area and performance index of kangaroo matrices are
larger than those in equivalent porcine matrices.
The study also addressed the logistics of tissue valve engineering, in particular stor-
age and availability of matrices. Decellularization procedures that take several days
are not uncommon [3]. The protocol used in this study took five days and could be
problematic when a valve is needed on short notice. Consequently, we report for the
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first time, the biomechanical effects of cryopreservation on xenogenic matrices by
evaluating them before and after cryopreservation. Cryopreservation did not signifi-
cantly influence the strength of matrices but cryopreserved matrices showed signifi-
cantly higher strain compared to non-cryopreserved matrices when subjected to the
same force. Of course, it is assumed that a matrix will be repopulated and regener-
ated within a certain time frame in an engineered valve. Whether the altered mechan-
ical properties will be sufficient to sustain the matrix during this time is unclear to
us. Based on the results of this study cryopreservation might not be appropriate for
storing a-cellular matrices
Porcine cells express gal-α1,3 isotope, the major xeno-antigen(s) recognised in pigs by
human natural antibodies [7]. A-vital cells in current bioprosthetic valves are widely
acknowledged to contribute to their calcific deterioration. A-cellular porcine matri-
ces are per definition devoid of cells. Nevertheless, when implanted in the sheep
model, a-cellular xenogenic matrices retained the propensity to calcify regardless of
whether they were of porcine or kangaroo origin. Indeed, we observed more calcifica-
tion in matrices than in a contemporary bioprosthetic valves. Recent evidence [8]
suggest that xenogenic scaffolds retain their immunogenicity. In this case, current
decellularization processes may not be sufficiently effective in removing immuno-
genic material. Current investigations by our laboratory are aimed at optimising
matrices by addressing their immunogenicity.
The study also presented a model for obtaining high densities of myofibroblasts for
tissue valve engineering from both arterial and dermal mesenchymal cells using
TGF-β1. TGF-β1, successfully trans-differentiated arterial and dermal fibroblast
yielding larger densities of myofibroblasts for cell seeding. However, TGF-β1 may
also inhibit the proliferation of fibroblasts within a leaflet. The cocktail of EGF,
bFGf and TGF-β can promote the proliferation and invasion of fibroblasts. TGF-b,
induced the expression of the invasion markers tenacin-C and N-caderine. EGF and
bFGF are potent inducers of proliferation. In the combination treatment of EGF, b
FGF and TGF-β, bFGF was capable of overcoming TGF-b inhibition, while exclu-
sively promoting proliferation. The triple combination EGF, bFGF and TGF-β is cur-
rently being used in our recellularization protocol. Numerous studies have indicated
that a bioreactor environment, which simulates hemodynamic conditions, may be
advantageous in the in vitro seeding of constructs [9,10]. In addition to seeding
matrices under static conditions, present investigations in our department also
make use of a custom made bioreactor for dynamic seeding in which matrices are
placed after they are mounted on a cylindrical support. [Fig 10a and 10b].
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Fig. 10. A mounted matrix (a). Temperature controlled Bioreactor for cell seeding under 
physiologic hydrodynamic conditions (b).
(a)
(b)
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Future Perspectives
Although a tissue engineered heart valve is a promising concept, its production is
not around the corner. Criteria as to what per definition constitutes a functional tis-
sue engineered valve are currently lacking and the definition of tissue engineering at
the beginning of this manuscript, while encompassing is not tissue specific.
Several questions persist:
– is an engineered construct supporting metabolizing cells a functional valve?
– to what extent is a tri-laminar structure required?
– how to test durability?
– how to guarantee vitality in vivo?
– what are the markers?
The lack of standards for judging constructs may have contributed, at least partly, to
the fact that successes in tissue valve engineering were being claimed in several areas
and even the American Heart Association Web site has an article entitled “ Tissue
Engineered valves give diseased hearts new life [1]. Despite the hype, we do not as yet
have the technology to guarantee a satisfactorily functioning valve. A recent report
with catastrophic consequences for patients emphasizes this point [2]. The valve
involved in the latter report was a tissue engineered valve produced by the commer-
cial enterprise CryoLife Inc., USA and named the Cryolife Synergraft®. It was pro-
duced from decellularized porcine valves and was implanted in pediatric patients in
Austria without reported long term animal studies, after receiving CE approval in
2000 [3]. Some valves failed only days after implantation and deaths were reported
after 7 days (patient aged 7 years), 6 weeks (patient aged 9 years) and one year
(patient aged 25 years). In another patient the valve was preventatively removed after
2 days. Progress is indeed slow but we need to be patient for while science might not
always be successful, patients are always first.
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Summary
This study addresses some fundamental issues involved in tissue engineering an aor-
tic valve. A tissue-engineered valve developed using three-dimensional synthetic or
biological scaffolds, which are repopulated with autologous cells, offers an opportu-
nity to overcome the limitations of current prosthetic valves. Current prosthetic
valves include mechanical, bioprosthetic and human homograft valves and they are
associated with major limitations. Mechanical valves are durable but require life-
long anticoagulation. Bioprosthetic valves and homografts avoid anticoagulation
but are a-vital with limited durability. A vital tissue engineered valve would require
no anticoagulation, utilize the body’s mechanisms for repair and re-modelling and
have the potential to grow. There is as yet, no functional tissue engineered valve
available. Tissue valve engineering is an evolving field of research, which faces several
critical issues, which include scaffold and cell selection as well as appropriate condi-
tions to accomplish repopulation.
Biological scaffolds were prepared from kangaroo and porcine aortic valves using a
detergent – enzymatic procedure. The logistics of having readily available biological
for use on short notice as in a clinical setting was addressed by investigating the fea-
sibility of cryopreserving matrices. Matrix biomechanical properties were evaluated
by determination of collagen and proteoglycan content and a burst test. The hydro-
dynamic properties of both types of matrices were evaluated using a left heart model
and their calcification potential in the sheep model. Myofibroblasts, the major phe-
notype of valvular interstitial cells, were obtained by establishing a model for arterial
and dermal fibroblast transdifferentiation by TGF-β1. Modulation of the prolifera-
tion and invasion of myofibroblasts in matrix repopulation was investigated with a
combination of growth factors including EGF, bFGF as well as TGF-β1.
Biological scaffolds can be procured from porcine and kangaroo aortic with preser-
vation of tissue strength but without eliminating their calcification potential. Kan-
garoo matrices showed superior hydrodynamics compared to porcine matrices.
TGF-β1 transdifferentiates fibroblasts into active myofibroblasts. A particular cock-
tail of growth factors can positively influence myofibroblast proliferation and inva-
sion into the matrix.
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Samenvatting
Deze studie behelst fundamenteel werk in het gebied van de tissue engineering van
kunstmatige hartkleppen. Een tissue-engineerde aortaklep, ontwikkeld uitgaande
van een drie dimensioneel synthetische of biologische matrix bezaaid met autologe
cellen, bezit het potentieel om de beperkingen van de huidige beschikbare artificiële
kleppen te overkomen. De huidige beschikbare kunstkleppen omvatten homografts
biologische en mechanische kleppen die elk majeure beperkingen kennen. Mechani-
sche kleppen, hoewel zeer duurzaam, vereisen levenslange anti-coagulatie. Biopros-
thesen en homografts daarentegen vereisen geen anticoagulatie maar hebben een
beperkte levensduur. Een levende tissue-engineerde hartklep veronderstelt geen anti-
coagulatie, kan zichzelf regenereren en heeft een groeipotentieel. Op dit ogenblik is
er echter geen dergelijke klep beschikbaar. Tissue engineering van hartkleppen is een
snel evoluerend gebied en kent verschillende aspecten zoals de selectie van de ideale
matrix en de te zaaien cellen, alsook de mogelijkheid en de ideale condities om een
matrix te herpopulariseren.
In deze studie werden biologische matrices ontwikkeld uit varkens of kangoeroe
kleppen na behandeling met een enzymatische detergent oplossing. De reden om
over te gaan op het gebruik van deze biologische matrices was gebaseerd op de reeds
lang bestaande kennis van de cryo-preserveerde homografts in de kliniek. De karak-
teristieken van deze matrices werden biochemisch getest door bepaling van het colla-
geen en de proteoglycans. Ook werd de weerstand mechanisch getest. De hydrodyna-
mische kenmerken werden nagegaan in een linker hart testmodel en het potentieel
tot calcificatie, de achillespees van alle bioprothesen, werd getest in het klassieke
schaapmodel. Myofibroblasten, het belangrijkste fenotype valvulaire interstitiële cel-
len, werden verkregen door transdifferentiatie van humane en schaap arteriële en
dermale fibroblasten na toedienen van TGF-β. De matrices herbezaaien door middel
van proliferatie en invasie van de myofibroblasten werd bekomen door het toedienen
van de groeifactoren EGF, bFGF in combinatie met TGF-β1.
Biologische matrices kunnen worden bekomen uit kangoeroe en porcien materiaal
met behoud van hun inherente sterkte doch zonder hun calcificatie potentieel te
neutraliseren. Kangoeroe matrices zijn hemodynamisch superieur ten opzichte van
varkenskleppen. De juiste combinatie van groeifactoren maakt het mogelijk om deze
myofibroblasten de matrix te laten binnendringen en uiteindelijk te herbezaaien.

The world of the senses is real, but it must be known for what it is:
unity appearing as multiplicity.
(The Upanishads)
